Research Progress on Self-Assembling Delivery Systems in Rheumatoid Arthritis Authors: Ling-ling Yu, Tian-tian Wei, Xie-yu Zhang, Jiang-xue Cheng, Li-na Quan, Bing-tao Zhai, Dong-yan Guo Published: 2026 ABSTRACT AbstractRheumatoid arthritis (RA)-affected joints are characterized by a distinct pathological microenvironment, featuring acidic pH, elevated reactive oxygen species (ROS), and overexpressed matrix metalloproteinases (MMPs), along with synovial hyperplasia, infiltration of activated immune cells (eg, M1 macrophages and Th17 cells), and pannus formation. Self-assembled drug delivery systems (SADDS) are constructed through non-covalent interactions—such as hydrophobic forces, hydrogen bonding, π-π stacking, metal coordination, and electrostatic interactions—enabling the formation of stable nanocarriers, including micelles, nanoparticles, and hydrogels. By leveraging intelligent, microenvironment-responsive design, SADDS demonstrate strong potential to enhance the targeting accuracy, controllability, and overall safety of RA treatment. This review, for the first time, systematically evaluates the design principles and synergistic mechanisms of local administration strategies based on self-assembled drug delivery systems for rheumatoid arthritis therapy from the perspective of four carrier types—nanoparticles, micelles, microneedles, and hydrogels.Keywords: rheumatoid arthritis, self-assembled drug delivery systems, nanoparticles, hydrogels, micelles, microneedles Introduction Rheumatoid arthritis (RA) is an autoimmune pathology principally defined by chronic, symmetrical polyarticular synovitis. Its pathogenetic cascade involves synovial hyperplasia, inflammatory cellular infiltration, articular cartilage degradation, and subchondral bone erosion.1 As per the 2020 Global Burden of Disease study, the worldwide incidence of rheumatoid arthritis (RA) approximates 17.6 million individuals, with an age-adjusted prevalence rate of 208.8 per 100,000 individuals. This signifies a 14.1% escalation from 1990.2 This disease not only significantly impairs patients’ quality of life but also substantially increases the risk of comorbidities such as cardiovascular diseases and osteoporosis, posing a serious public health challenge.3 Current clinical interventions for RA primarily rely on NSAIDs (non-steroidal anti-inflammatory drugs), glucocorticoids, and conventional/biological DMARDs (disease-modifying antirheumatic drugs). However, conventional systemic administration strategies are limited by the blood-synovial barrier and intra-articular hypertension (10–30 mmHg), resulting in local joint drug concentrations often below 5% of systemic exposure levels.4 To compensate for the inefficiency of targeted delivery, clinicians often employ high-frequency, high-dose administration, which may subsequently induce hepatic and renal impairment, gastrointestinal toxicity, and secondary infections.5 Furthermore, the acidic microenvironment within RA lesions, the surge of reactive oxygen species (ROS), and the high expression of matrix metalloproteinases (MMPs) further exacerbate drug inactivation and delivery barriers. Although intra-articular injection can temporarily increase local drug concentrations, repeated invasive procedures significantly compromise patient adherence. On the other hand, first-line drugs such as methotrexate exhibit a delayed onset of action (4–8 weeks), and approximately 30–40% of patients develop resistance due to overexpression of efflux pumps or genetic polymorphisms; long-term use is also associated with dose-dependent toxicities such as hepatic fibrosis and bone marrow suppression. Traditional nanocarriers (eg, liposomes, polymer micelles) suffer from low encapsulation efficiencies (<10%), making them inadequate for achieving efficient lesion-specific accumulation and precise controlled release required for long-term RA treatment. Therefore, it is crucial to develop novel drug delivery strategies that combine high drug-loading efficiency, excellent targeting capability, and low systemic toxicity. In contrast to traditional nanocarriers (such as liposomes and polymer micelles), which are limited by low encapsulation rates (<10%) and thus fail to meet the demands for efficient drug accumulation at lesions and precise controlled release in long-term RA therapy, self-assembling delivery systems offer significant advantages. Particularly noteworthy is the carrier-free self-assembling drug delivery system that integrates drug and excipient functions. These systems spontaneously form nanostructures through non-covalent interactions such as hydrophobic effects, hydrogen bonds, or π-π stacking, eliminating the need for exogenous carrier materials while achieving ultra-high drug loading capacity alongside excellent biocompatibility and biodegradability.6,7 This system spontaneously constructs nano/micron-scale structures through non-covalent interactions such as hydrophobic effects,8 hydrogen bonds, or π-π stacking, eliminating the need for exogenous carrier materials while achieving ultra-high drug loading capacity alongside excellent biocompatibility and biodegradability. This fundamental design principle has given rise to distinct functional characteristics across various delivery platforms: SADDS not only prolongs its systemic circulation half-life and achieves passive targeting via enhanced permeability and retention (EPR) effect, but also enables precise targeting of macrophages and fibroblast-like synovial cells through surface ligand modification.9 More importantly, SADDS ingeniously leverages pathological characteristics of the RA microenvironment—such as low pH, high ROS levels, or elevated MMP concentrations—to trigger intelligent drug-responsive release, thereby maximizing local therapeutic efficacy at the lesion site while significantly reducing systemic toxic side effects. Additionally, SADDS exhibits multi-component co-assembling capability, enabling synergistic delivery of anti-inflammatory agents and immunomodulators, thus establishing a novel paradigm for multimodal intervention in rheumatoid arthritis (RA).10–12 Furthermore, SADDS exhibits multi-component co-assembling capability, enabling synergistic delivery of anti-inflammatory drugs and immunomodulators, thereby establishing a novel paradigm for multimodal intervention in rheumatoid arthritis (RA).13 However, the translation of this technology into clinical applications faces multiple barriers: the self-assembly process is highly sensitive to temperature, pH, ionic strength, and hydrodynamic parameters, making batch reproducibility challenging during scale-up; the structural stability of non-covalent bonding systems remains uncertain under complex physiological conditions and during long-term storage; repeated dosing required for chronic rheumatoid arthritis (RA) treatment may induce immunogenicity or off-target effects; furthermore, standardized characterization and quality control protocols for such dynamic assembly systems have not yet been established, further complicating regulatory approval processes. Although substantial literature has been published on RA nanodrug delivery, existing reviews still exhibit significant gaps: most studies focus on systemic administration routes while inadequately exploring localized drug delivery strategies within joint cavities;14–16 the literature predominantly analyzes individual carrier types in isolation, lacking systematic cross-platform comparisons (eg, nanoparticles, hydrogels, microneedles);17–20 and some reviews fail to adequately elucidate the intrinsic coupling between the pathological microenvironment of RA and intelligent drug-release mechanisms.21,22 To address these shortcomings, this study systematically searched peer-reviewed publications published in PubMed, Web of Science, and X-MOL databases from January related studies focused on RA treatment. For the first time, this review integrates four self-assembling platforms—nanoparticles, micelles, microneedles, and hydrogels—from both the perspectives of “lesion-specific microenvironment triggering” and “localized precision drug delivery”, elucidating how RA pathological characteristics guide rational carrier design and objectively evaluating the clinical applicability and limitations of various delivery systems. Furthermore, it examines key translational challenges such as targeting specificity, process scalability, long-term safety, and regulatory compliance, while proposing promising approaches for cutting-edge advancements like multi-signal synergistic responses and continuous microfluidic synthesis, aiming to provide theoretical foundations and design insights for developing next-generation efficient RA drug delivery systems for clinical application. Pathophysiological Characteristics of RA The pathological essence of rheumatoid arthritis (RA) is a complex network system comprising immune cells, inflammatory factors, and bone metabolism cells.23 The core characteristics of this system are autoimmune-driven chronic inflammation and progressive bone destruction. The core features of its microenvironment can be summarized across three levels: biochemical abnormalities, cellular infiltration, and tissue structural alterations. These features collectively form the targeted foundation for RA-specific drug delivery (Figure 1). Pathological features and immunopathogenic mechanisms of rheumatoid arthritis (RA). Teal arrow: nanocarrier self-assembly; blue arrows: delivery to RA joints; black arrow: MMP-2-responsive release; light blue arrow: elevated ROS in macrophages. (A) Normal joint structure (healthy control). (B) Synovial cavity microenvironment: low pH (6.0–6.5), elevated ROS/RNS, reduced GSH, and high MMP expression. (C) RA-affected joint: synovial hyperplasia, pannus formation, inflammatory infiltration, cartilage destruction, bone erosion, angiogenesis, immune cell activation (monocyte/macrophage, T cell, B cell, dendritic cell), pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), osteoclast differentiation, and MMP-mediated cartilage degradation. The synovial cavity in RA exhibits distinctive biochemical characteristics that collectively form an imbalanced microenvironment driving disease onset and progression. At its core lies a low pH (6.0–6.5), elevated levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS), reduced glutathione levels, and high expression of matrix metalloproteinases (MMPs).24 These biochemical characteristics provide ideal conditions for the design of stimulus-responsive nanocarriers.25 Reduced GSH (Glutathione) levels in synovial tissue and serum, coupled with elevated oxidized glutathione (GSSG) ratios, resulted in decreased GSH/GSSG ratios, indicating severe impairment of the antioxidant defense system. GSH depletion activates the NF-κB and NLRP3 inflammasome pathways, promoting the release of proinflammatory factors such as TNF-α, IL-1β, and IL-6. Simultaneously, it weakens the cell’s ability to clear reactive oxygen species (ROS), exacerbating chondrocyte apoptosis and bone erosion. Notably, the acidic environment arises from local tissue anaerobic metabolism and cellular necrosis. This environment not only intensifies the inflammatory response but also provides conditions for triggering drug release from delivery systems, such as hydrazone-linked carriers. pH-sensitive materials (eg, polymers containing amide bonds) can trigger drug release under acidic conditions. Local tissue metabolic abnormalities combined with hypoxia cause synovial fluid pH to decrease (typically from 7.4 to around 6.0), serving as a trigger signal for acid-sensitive drug delivery systems. Excessively produced ROS and RNS cause oxidative damage to lipids, proteins, and DNA while activating key pro-inflammatory signaling pathways like NF-κB. Simultaneously, they themselves serve as targets for ROS-responsive nanomaterials (eg, carriers containing sulfide bonds). Excessive activation of MMPs (such as MMP-1, MMP-3, MMP-9) is aimportantcause of irreversible degradation of the extracellular matrix of cartilage (such as collagen and proteoglycans). Among these, TNF-α and IL-1β are key central factors. Produced by activated macrophages and FLS, they powerfully promote the expression of other inflammatory cytokines (such as IL-6 and IL-17), chemokines, and adhesion molecules, forming a positive feedback loop. The IL-17/IL-23 axis plays a crucial role in driving Th17 cell differentiation and maintaining their function, further amplifying inflammation. At the tissue level, the pathological features of RA manifest as progressive destruction and abnormal remodeling of the synovium, cartilage, and bone. Significant alterations include synovial hyperplasia and the formation of pannus. Activated fibroblast-like synovial cells (FLS) acquire a “tumor-like” phenotype, exhibiting abnormal proliferation and resistance to apoptosis. Together with neovascularization and inflammatory cells, they form a highly vascularized, invasive tissue known as the pannus. This tissue overlays the articular cartilage surface like a membrane and directly erodes cartilage and subchondral bone by secreting MMPs and pro-inflammatory mediators, forming the structural basis for joint destruction. This process is accompanied by abnormal vascular proliferation. Driven by factors such as VEGF (Vascular Endothelial Growth Factor), the synovial tissue generates extensive tortuous, highly permeable neovascularization. This not only nourishes the growth of inflammatory tissue but also facilitates the extravasation of vascular contents. Simultaneously, impaired local lymphatic drainage contributes to an enhanced permeation and retention (EPR) effect.26 The EPR effect enables nanoscale drug carriers to selectively accumulate and persist in inflamed joints, providing a theoretical basis for passive targeted delivery.27 Additionally, tertiary lymphoid structures (TLS) form within the synovial tissue, containing clusters of T cells and B cells along with follicular-like structures. This causes immune cells that should circulate systemically to become locally activated, continuously producing autoantibodies and pro-inflammatory factors. Pro-inflammatory factors (such as VEGF) increase synovial vascular permeability while simultaneously impairing the lymphatic drainage system.28 Ultimately, these processes lead to cartilage degradation and bone erosion. The pathogenesis of RA results from the abnormal activation and interaction of multiple immune cells with stromal cells, forming a complex cellular network. T lymphocytes: CD4+ T cells differentiate into short-lived effector T cells (SLECs) due to DNA repair defects (eg, insufficient ATM and MRE11A expression). These cells exhibit tissue invasiveness, triggering pyroptosis via mitochondrial DNA damage. They release pro-inflammatory factors such as TNF and IFN-γ, directly activating osteoclasts and promoting bone resorption; B lymphocytes: B cells produce autoantibodies like anti-citrullinated protein antibodies (ACPA), forming immune complexes that deposit at the bone-tissue interface. This indirectly activates the complement system and macrophages, exacerbating inflammatory bone erosion; Synovial macrophages further drive bone destruction: Proinflammatory subpopulations (eg, SC-M1) highly express TNF and IL-1β, directly stimulating osteoclast differentiation and activation, while the absence of protective macrophages (eg, SC-M2) disrupts the reparative balance in the bone microenvironment.29 Macrophages: In RA, the M1/M2 ratio is imbalanced, with M1 macrophages predominating. They exacerbate bone destruction by enhancing osteoclast differentiation and activation (eg, through direct stimulation of bone resorption via TNF-α signaling).30 Macrophages infiltrate extensively at the synovial membrane and cartilage-vascular plate junction, promoting bone resorption and erosion by producing proinflammatory cytokines that stimulate osteoclast differentiation and activation; TNF-α enhances receptor activator of nuclear factor κB ligand (RANKL) expression, thereby activating osteoclastogenesis, while cytokines such as IL-1β and IL-17 exacerbate subchondral bone degradation by upregulating matrix metalloproteinases (MMPs) and promoting inflammatory networks. Macrophages themselves can differentiate into osteoclasts, directly participating in bone destruction. Particularly in the subchondral region, they form “vascular capillaries” structures, leading to irreversible joint damage.31 Furthermore, fibroblast-like synovial cells (FLS) —as the primary matrix cells—no longer function as quiescent structural cells but instead transform into activated effector cells.32 They directly destroy cartilage, activate osteoclasts, and recruit additional inflammatory cells by secreting mediators such as MMPs, receptor Activator of Nuclear Factor-kappa B Ligand (RANKL), and IL-6. Overexpression of RANKL leads to excessive osteoclast activation, resulting in bone erosion. Mast cells amplify inflammation and tissue damage by releasing stored mediators like histamine and tryptase, while neutrophils contribute through the release of proteases and neutrophil extracellular traps (NETs). Through intricate interactions, these cells collectively sustain the chronic inflammatory and destructive processes characteristic of RA. Design Principles for Self-Assembling Drug Delivery Systems Self-assembled Drug Delivery Systems (SADDS) leverage intermolecular noncovalent interactions to form stable nanostructures—such as nanoparticles, micelles, and gels—through spontaneous molecular self-organization in aqueous or physiological conditions. This enables drug loading, protection, and controlled release.33 The core of its design lies in precisely regulating self-assembly driving forces, drug loading strategies, surface modifications, and stimulus-responsive mechanisms to match the characteristics of the disease microenvironment, thereby achieving targeted, efficient, and low-toxicity drug delivery. Self-Assembly Driving Forces and Classification The formation of self-assembled systems relies on the synergistic action of multiple noncovalent interactions, including hydrophobic interactions, π–π stacking, hydrogen bonding, electrostatic interactions, and coordination interactions.34 These intermolecular forces not only affect the stability and morphology of the system but also influence drug loading efficiency and release behavior. Hydrophobic Interactions Drive In hydrophobic interaction-driven self-assembly systems, hydrophobic interactions represent a ubiquitous non-specific force prevalent in biological systems.35 When molecules rearrange in an aqueous environment, hydrophobic regions tend to cluster together, thereby reducing contact with water molecules and lowering the system’s total free energy.36 Self-assembling materials are commonly found in poly(lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-PEG) copolymers and natural polysaccharides such as hyaluronic acid. These materials are engineered to exhibit amphiphilic properties, where hydrophobic segments (eg, PLGA blocks, acetylated regions of chitosan) interact with hydrophilic segments (eg, PEG, carboxymethyl groups), enabling spontaneous self-assembly into core-shell nanomicelles in aqueous solutions. For instance, researchers combined PLGA (hydrophobic core) with PEG (hydrophilic shell) via hydrophobic interactions to form core-shell nanospheres; driven by hydrophobic interactions, the nanoparticle half-life extended to 5.979 hours (approximately 6-fold increase), with clearance significantly reduced to 103.68 L/h/kg. The hydrophobic core enables sustained drug release, achieving a cumulative release rate of 56.9% over 9 days while optimizing drug exposure by delaying Tmax to 3 hours. This system significantly enhances RA therapeutic efficacy through hydrophobic-hydrophilic equilibrium.37 Electrostatic Interaction-Driven Electrostatic interactions are essentially a spontaneous assembly process mediated by Coulomb forces between molecules or groups bearing opposite charges.38 The core mechanism relies on precise charge matching. In physiological conditions, positively charged cationic polymers (such as chitosan) form stable nanocomposites with negatively charged anionic components (such as sodium tripolyphosphate) through electrostatic attraction. The mildly acidic environment (pH 6.5–6.8) in RA-affected joints enhances protonation of cationic polymers, thereby strengthening electrostatic interactions. For example, positively charged chitosan (cationic polymer) spontaneously assembles with negatively charged sodium tripolyphosphate (anionic crosslinker) via electrostatic attraction, forming core-shell structured nanoparticlesthatremain stable for 5 days (no color change, precipitation, or turbidity), achieving a curcumin encapsulation efficiency (EE) of 99.97% and drug loading capacity (DLC) of 11.34%. This highlights the critical role of electrostatic interactions in efficient drug delivery. The positive charge of chitosan electrostatic bonds with the negative mucosal layer, prolonging intestinal retention time and enhancing absorption.39 Hydrogen Bonding Hydrogen bonds are a special type of dipole-dipole interaction that occurs between hydrogen atoms and more electronegative atoms such as nitrogen, oxygen, or fluorine.40 Such bonds can form within the same molecule (intramolecular) or between different molecules (intermolecular), significantly influencing physicochemical properties.41 Its mechanism is based on dipole-dipole interactions between electronegative atoms (such as O, N) and hydrogen atoms, which are widely present in natural polysaccharides (eg, hyaluronic acid, chitosan) and synthetic polymers (eg, polyvinylpyrrolidone)—common carrier materials for RA. During self-assembly, hydrogen bonds not only facilitate the precise spatial positioning of molecules but also enhance intermolecular forces to ensure the stability of the self-assembled structures. As a pivotal molecular force, hydrogen bonding interactions exhibit high directionality, reversibility, and specific recognition capabilities. These features confer core functional advantages in enhancing drug efficacy, improving targeting precision, and enabling synergistic therapeutic approaches.42 π-π Pileup Drive π-π stacking is a key assembly force dominated by electron cloud interactions between aromatic ring systems.43 This interaction primarily occurs in molecules rich in conjugated structures, such as anthraquinone, pyrene, and porphyrin rings in drug molecules, or benzene rings and pyridine rings in carriers. Since π-π stacking does not alter the fundamental structure or functional properties of drugs, it has been widely utilized in the design of drug loading and delivery systems.44 Researchers elucidated through the co-assembly behavior of methotrexate (MTX) and baricitinib (BTN) that the synergistic interaction between π-π stacking and hydrogen bonding in their aromatic ring structures—such as the pyrimidine ring of MTX and the pyrimidine ring of BTN—directly drives the formation of vesicular nanostructures (MB NVs), significantly enhancing drug loading capacity (DLC reaching 34.29%); under the high reactive oxygen species (ROS) environment of RA synovium, polyphenylene sulfide-polyethylene glycol (PPS-PEG) carrier degradation dissociating the π-π packing structure to accelerate drug release (78.11% released within 12 hours under 500 μM HClO), achieving site-specific delivery.45 Metal Coordination-Driven Coordination-driven self-assembly is an effective method for constructing supramolecular metal cages and functional materials by utilizing the directional coordination bonds between metal ions and organic ligands.46 Through directed bonding between metal ions (eg, Fe3⁺) and biomolecules containing coordinating groups (eg, carboxyl, imidazole groups), it constructs structurally precise nanocarriers that can be assembled into diverse morphologies ranging from discrete structures to infinite networks. Coordination-driven self-assembly offers significant synthetic advantages, including fewer steps, rapid and convenient final product construction, and inherent self-correction and defect-free assembly characteristics.47 This self-assembly strategy relies on metal ions or metal complexes as coordination centers that combine with biomolecular building blocks. Through the formation of directed coordination bonds, they spontaneously organize and assemble into larger, more ordered structures.48 For example, the zeolite imidazolate framework (ZIF-8) formed through coordination self-assembly between zinc ions and 2-methylimidazole can efficiently load hydrophobic anti-rheumatic drugs (such as methotrexate). It utilizes the acidic environment of the RA synovial microenvironment to trigger coordination bond dissociation, enabling precise drug release.49 The coordination assembly of iron ions with natural polyphenolic ligands (such as tannic acid) enables the construction of metal-polyphenol networks with antioxidant and inflammation-targeting functions, synergistically enhancing therapeutic efficacy.50 Drug Loading Method Drug loading strategies are crucial for the efficacy and safety of self-assembling drug delivery systems, primarily categorized into physical encapsulation and chemical bonding. Physical encapsulation relies on non-covalent interactions to encapsulate drugs within the carrier, while chemical bonding—particularly metal coordination bonds—achieves smart, trigger-activated drug release through covalent bonds that firmly anchor the drug to the carrier. Physical Encapsulation Physical encapsulation methods load drugs into self-assembled structures via non-covalent interactions such as hydrophobic forces, electrostatic attraction, and hydrogen bonding. Physical encapsulation techniques—such as encapsulation within nanocarriers (eg, the aqueous core of liposomes or the matrix of polymeric nanoparticles)—effectively enhance the encapsulation efficiency of hydrophilic anti-RA drugs like methotrexate or biologics. For instance, methotrexate (MTX), a first-line drug, often faces efficacy limitations due to rapid clearance and systemic toxicity. Physical encapsulation systems like gellan gum (GG) microspheres, prepared via W/O emulsion solvent diffusion, can significantly improve drug delivery efficiency; GG microspheres achieved an MTX encapsulation efficiency of 84.8% ± 1.68%, with a drug loading capacity of 6.45% ± 0.07%, demonstrating their high efficiency in loading hydrophilic drugs. Fourier Transform Infrared Spectroscopy (FTIR) spectroscopy confirmed that the drug is incorporated into the polymer matrix through physical interactions without chemical bonding, ensuring drug stability.51 Chemical Bonding and Responsive Fracture Chemically bonded drug delivery systems stably conjugate drugs to carrier materials through covalent bonds, demonstrating unique advantages in rheumatoid arthritis (RA) therapy. Metal coordination bonds, as a significant chemical bonding approach, optimize nanodrug performance by forming directional, reversible coordination interactions between metal ions (eg, Fe3⁺, Au⁺/Au3⁺) and electron-rich groups (eg, carboxyl, amino) in drug molecules. Coordinative bonding enables high drug loading through multidentate ligand design, such as the Fe─O/Fe─N bond-mediated binding of methotrexate (MTX) to iron oxide nanoparticles (SPIONs).52 The drug loading capacity reaches 15–20%, with an encapsulation efficiency exceeding 90%, significantly higher than physical adsorption methods (10%). Researchers achieved stable metal-organic frameworks (MOFs) by directing coordination between Fe3⁺ and Tetrakis(4-carboxyphenyl)porphyrin (TCPP) ligand carboxyl groups, significantly optimizing drug loading performance with an encapsulation rate of 93.74% ± 1.65% attributed to the ordered porous structure formed by coordination bonds, ensuring efficient drug loading. In the acidic microenvironment of RA inflammation (pH 6.5), the coordination bonds are moderately weakened, enabling controlled release—rapid release of 55% within the initial 4 hours, with cumulative release reaching 87.82% at 24 hours.53 Surface Modification and Targeting Strategies Functionalization of self-assembled nanodelivery systems is a core strategy for enhancing their therapeutic efficacy and safety. Among these, polyethylene glycol (PEG) modification confers “stealth” and stability to the carrier, significantly prolonging circulation time and enabling microenvironment-responsive drug release at the target site. Ligand-targeted modification, utilizing specific molecules such as hyaluronic acid (HA) and mannose, actively guides carrier accumulation in inflamed joints and specific immune cells, advancing from passive diffusion to active recognition. Polyethylene Glycolation Polyethylene glycol (PEG) modification stands as one of the most widely adopted and mature surface functionalization strategies in current self-assembled nanoscale drug delivery systems.54 Zewail et al55 further demonstrated that PEGylated lipid-polymer nanoparticles (PEG-LCNPs) for oral leflunomide exhibited anti-arthritis efficacy. They improved drug release (91.79% over 24 h) via a PEG protective layer that mitigates charge shielding, thereby enhancing electrostatic repulsion and colloidal stability. In the treatment of rheumatoid arthritis (RA), PEG-modified self-assembled carriers such as Poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL) micelles and PEG-TGMS hydrogels demonstrate excellent synovial retention and sustained drug release capabilities. The flexible surface structure of PEG enhances wettability and permeability between the carrier and synovial tissue, enabling stable dispersion within the joint cavity microenvironment. Through sustained-release mechanisms, it continuously delivers anti-inflammatory drugs, achieving prolonged anti-inflammatory effects while reducing administration frequency. Additionally, PEG modification reduces degradation of the carrier by enzymes and free radicals in synovial fluid, enhancing the formulation’s structural integrity and controlled drug release under highly inflammatory conditions. The study by Zewail et al55 further demonstrated that PEGylation modification reduces the hepatotoxicity of leflunomide (LEF) by prolonging the systemic circulation half-life of nanoparticles and decreasing hepatic exposure to the toxic drug. Consequently, the PEGylation strategy not only optimizes the physicochemical properties and drug release behavior of nanocarriers but also synergistically enhances the therapeutic index and safety through a “stealth” effect. Ligand-Targeted Modification Ligand-targeted modification is a key strategy for achieving active targeting and precision therapy in self-assembling nanocarrier systems. Its core principle involves surface-modifying specific recognition molecules, enabling nanocarriers to actively recognize and bind receptors highly expressed in inflammatory microenvironments, thereby facilitating targeted drug accumulation and efficient delivery. A targeting ligand is a molecule that specifically binds to target cells or tissues, recognizing and attaching to specific receptors or molecular markers on the surface of target cells. For example, Folate receptor β (FR-β) is specifically expressed on activated macrophages in rheumatoid arthritis (RA) lesions but not in normal tissues. Folic acid-modified nanocarriers exploit this receptor for active targeting to inflamed joints. FR-β also serves as a biomarker and therapeutic target for RA.56 Currently reported targeting ligands primarily include proteins and peptides (short peptides, polypeptides, etc)., nucleic acids (nucleic acid aptamers, etc)., sugars (mannose, galactose, etc)., and their derivatives, as well as functional polymers and magnetic nanoparticles. Targeted drugs can selectively deliver therapeutic payloads to diseased cells, effectively reducing non-specific uptake and minimizing toxic side effects on normal tissues and healthy cells, thereby enhancing treatment safety and efficacy.57 In self-assembling polymeric nanomedicines, natural polymers, including hyaluronic acid, heparin, and chitosan, are widely used as ligands for targeted delivery due to their inherent biocompatibility and ease of chemical modification.58 Among numerous ligand materials, hyaluronic acid (HA) stands as one of the most representative natural polysaccharides, possessing both self-assembly properties and targeting capabilities. Through HA modification, self-assembling carriers achieve a triple process of “adhesion–permeation–retention” within the joint cavity, significantly enhancing drug residence time and local concentration at the lesion site, thereby strengthening anti-inflammatory and immune-modulating effects. Beyond HA, other ligands such as mannose and folic acid are also widely employed for surface functionalization in self-assembling systems. Stimulus-Response Release The pathological microenvironment of rheumatoid arthritis (RA) exhibits significant spatial and chemical heterogeneity, characterized by decreased synovial tissue pH (approximately 6.0), elevated reactive oxygen species (ROS)levels, and overexpression of enzymes such as matrix metalloproteinases (MMPs).59 Smart drug delivery systems can target drugs to diseased areas and release them in response to external or internal stimuli.60 Self-assembling drug delivery systems convert environmental signals into drug release drivers, enabling on-demand, localized, and temporally/spatially controllable precision therapy at RA lesions. This significantly enhances therapeutic efficacy while reducing systemic toxic side effects (Figure 2). Schematic of internal and external stimuli activating responsive nanomedicine at rheumatoid arthritis lesions. Red arrows indicate that endogenous stimuli (A) and exogenous physical stimuli (C) target the inflamed joint (B). Up/down arrows represent increased/decreased biomarker levels in RA microenvironment. (A) Internal microenvironmental triggers: acidic pH (~6), enzymes, and redox imbalance (elevated ROS, depleted GSH). (B) Pathological microenvironment of RA joint featuring pH≈6, ROS↑, GSH↓ and MMPs↑. (C) External physical stimuli for remote control: ultrasound, light, magnetism and temperature. pH Response In the early stages of rheumatoid arthritis (RA), fibroblast-like synovial cells (FLSs) surrounding the joints proliferate rapidly. The proliferation of FLSs and the local inflammatory response at the site of arthritis increase metabolic activity, leading to hypoxia. This triggers anaerobic glycolysis and lactic acid formation.61 Chronic inflammation leads to impaired synovial blood flow, heightened cellular metabolism, and lactic acid accumulation, resulting in persistent tissue acidification (pH approximately 6.0–6.5). This pH gradient provides a natural stimulus-triggering condition for acid-responsive self-assembly systems.62 PH-responsive self-assembling systems typically employ amphiphilic molecules or polymers as dynamic building blocks.63 Upon entering an acidic microenvironment, the rupture of acid-sensitive bonds or changes in ionization levels disrupt intermolecular equilibrium, triggering either structural disassembly of the self-assembled complex or expansion of its shell layer. This process is accompanied by rapid drug release, enabling the system to adaptively regulate pharmacokinetics according to the severity of inflammation. pH-responsive self-assembled systems offer distinct advantages: they avoid systemic exposure and toxic side effects by delivering drugs primarily at the lesion site; release kinetics are controllable, with precise regulation of release rates achievable through designing bond energies and polymer hydrophilic-hydrophobic ratios. Enzyme Response Chronic inflammation in RA leads to sustained activation of synovial cells, osteoclasts, and immune cells, significantly upregulating multiple enzymes, including matrix metalloproteinases (MMP-2, MMP-9), lysozyme, and elastase. These enzymes not only participate in extracellular matrix degradation but also serve as ideal endogenous trigger signals for designing enzyme-responsive carriers.64 By incorporating sensitive motifs within self-assembling materials—such as MMP-recognizable peptide chains or enzyme-sensitive linkages—drugs can achieve “on-demand release” at the target site, enabling precise spatial and temporal therapy. Enzyme-responsive self-assembly systems typically comprise amphiphilic polymers, peptides, or degradable crosslinked networks. Upon entering inflamed tissues, locally overexpressed enzymes recognize and cleave sensitive bonds within the system, causing disassembly or degradation of the self-assembled structures and triggering drug release. This release mechanism differs from traditional diffusion- or permeation-dependent approaches, enabling targeted activation at the cellular or subcellular level. It significantly enhances local drug concentrations while minimizing systemic side effects. Redox Response In the inflammatory microenvironment of RA, reactive oxygen species (ROS, such as O2− and H2O2) are significantly elevated, creating a unique chemical environment characterized by the coexistence of strong oxidation and strong reduction.65 Research reports indicate that circulating neutrophils in RA patients exhibit an abnormal activation phenotype characterized by delayed apoptosis and increased production of reactive oxygen species (ROS) and cytokines, leading to bone and joint damage.66 This endogenous imbalance not only drives pathological responses but also provides a unique trigger signal for the design of self-assembling carriers.67 By introducing sensitive chemical bonds susceptible to oxidative or reductive cleavage (such as disulfide bonds, sulfide ether bonds, selenide ether bonds, or selenide structures) into self-assembling systems, drugs can achieve selective release under inflammatory conditions characterized by high reactive oxygen species (ROS) or high glutathione (GSH) levels, thereby enabling pathologically signal-driven precision regulation. Redox-responsive self-assembling systems typically utilize amphiphilic polymers, peptide derivatives, or organic-inorganic hybrid structures as their foundation. Upon entering RA lesions, redox gradients trigger chemical bond cleavage within the system, causing the carrier structure to undergo deaggregation or swelling, thereby enabling targeted drug release. Response to External Stimulation Unlike endogenous response systems that rely on pathological signals (such as pH, ROS, or enzymes), external stimulus-responsive systems achieve spatiotemporal programmable control of drug release by introducing adjustable, reversible external physical signals (such as light, magnetism, ultrasound, or temperature) as triggering factors.68 This breakthrough overcomes the limitations of traditional passive release, enabling active control over “when, where, and how much” drug is delivered under medical supervision. This significantly enhances treatment personalization and safety. For instance, physical agents like light and sound demonstrate unique advantages in rheumatoid arthritis (RA) therapy. Near-infrared light (eg, 808 nm laser) can elevate local temperatures to 42–45°C via the photothermal effect, inducing apoptosis in diseased synovial cells and inhibiting vascular endothelial growth. Concurrently, photodynamic therapy utilizes photosensitizers (eg, Ce6) to generate reactive oxygen species upon laser activation, eliminating M1 macrophages.69 Ultrasound enhances synovial tissue permeability through mechanical effects, promoting drug penetration, and disrupts pathological vascular networks via acoustic cavitation. Low-frequency pulsed ultrasound (eg, 40 kHz) also suppresses TNF-α and IL-6 expression.70 This coupling mechanism of “exogenous signals + intrinsic self-assembly dynamics” enables the system to maintain structural stability while exhibiting high responsiveness. External stimulus-responsive self-assembled systems can achieve localized drug release through non-invasive external stimulation, minimizing systemic exposure and side effects. The response process is repeatable and programmable, allowing multiple adjustments to drug release rhythms to match inflammatory cycles. They exhibit strong potential for multimodal integration, enabling synergistic use with photothermal, magnetothermal, and sonodynamic therapies to achieve “diagnosis-treatment integration”. Materials and Characterization Approaches for Self-Assembling Drug Delivery Systems Materials for RA-targeted self-assembling systems include natural/semi-synthetic/synthetic polymers, inorganic compounds, and MOFs (Table 1). Characterization methods depend on carrier type: nanoparticles/micelles require size, zeta potential, CAC, encapsulation efficiency, and morphology; hydrogels need rheology, swelling ratio, and phase transition; microneedles require fracture force and drug distribution uniformity. All systems should assess in vitro release, stability, and batch consistency. A factorial characterization strategy is essential to meet regulatory requirements and support translation from structure validation to clinical readiness. Table 1Functional Materials for Self-Assembling Drug Delivery SystemsMaterial CategorySpecific MaterialsSelf-Assembly Driving Force/MechanismAdvantagesReferencePolysaccharidesHyaluronic Acid (HA)Hydrogen bonds, hydrophobic interactions, electrostatic interactionsBiocompatible and DegradableCD44-TargetingEnzyme-Responsive[71–78]Chitosan (CS)Ion crosslinking, polyelectrolyte compositeMucoadhesive and Permeability-EnhancingInherently Antibacterial and Antifungal[79–85]Dextran/Dextran sulfateHydrophobic interactionsExcellent Solubility and Invisible EffectHeparin-like Anticoagulant ActivityP-selectin Inhibitory and Anti-inflammatory Action[86–88]Cyclodextrin (CD)π-π stackingEncapsulates Hydrophobic DrugsEnhances Solubility and StabilityGenerally Recognized As Safe (GRAS)[89–92]ProteinsHuman Serum Albumin (HSA)Hydrophobic interactionsEndogenous and BiocompatibleLong Circulating Half-LifeInherent Targeting Capability[93–96]GelatinThermoreversible gelation, enzymatic hydrolysisCollagen-Derived and BiocompatibleThermoresponsive and InjectableRGD-Containing for Cell Adhesion[97–99]PeptidesPeptideHydrogen bonds, π-π stacking, electrostatic interactionsProgrammable Sequence and Stimuli-ResponsivePrecise Response to Enzymes/pHSelf-Assembling Nanofibers and Tubular Structures[100–107]Semi-synthetic polymer materialsHA - PEG copolymers, chitosan derivativesHydrophobic interactionSynergy of Natural Bioactivity and Synthetic ControlCombines Long-Circulation (eg, PEG-like)Highly Customizable Functionality[71,108–110]Synthetic Polymer MaterialsPoly(lactic-co-glycolic acid)(PLGA), Poly(lactic-co-glycolic acid)-poly(ethylene glycol) copolymer(PLGA - PEG)Hydrophobic interactionsTunable Degradation and Release KineticsPrecise Control via Molecular Weight/RatioFDA-Approved with Proven Safety[111]Metal IonsFe2⁺/Fe3⁺ Mg2⁺Mn2⁺Electrostatic adsorptionFe2⁺: Ferroptosis-driven cell clearance via ROS/GSH axis.Mg2⁺: Safe immunomodulation, anti-inflammatory, and anti-erosion.Mn2⁺: Reverses hypoxia and reprograms the inflammatory microenvironment.[112–118]Inorganic NanoparticlesMagnetic nanoparticles (MNPs): Fe3O4, Gold nanoparticles (AuNPs)Metal coordinationMNPs: Multimodal theranosticsAuNPs: Photothermal/chemodynamic therapy and immunomodulation for multimodal diagnosis and therapy.[119–125]Inorganic–Organic Hybrid MaterialsMetal–organic frameworks (MOFs): eg, MIL-100(Fe), MTX-TA/Fe3⁺Metal coordinationHigh surface area, tunable pores, large drug-loading capacity.Enable sustained, targeted delivery and imaging.[126–133] Functional Materials for Self-Assembling Drug Delivery Systems Biocompatible and Degradable Biocompatible and Degradable CD44-Targeting CD44-Targeting Enzyme-Responsive Enzyme-Responsive Mucoadhesive and Permeability-Enhancing Mucoadhesive and Permeability-Enhancing Inherently Antibacterial and Antifungal Inherently Antibacterial and Antifungal Excellent Solubility and Invisible Effect Excellent Solubility and Invisible Effect Heparin-like Anticoagulant Activity Heparin-like Anticoagulant Activity P-selectin Inhibitory and Anti-inflammatory Action P-selectin Inhibitory and Anti-inflammatory Action Encapsulates Hydrophobic Drugs Encapsulates Hydrophobic Drugs Enhances Solubility and Stability Enhances Solubility and Stability Generally Recognized As Safe (GRAS) Generally Recognized As Safe (GRAS) Endogenous and Biocompatible Endogenous and Biocompatible Long Circulating Half-Life Long Circulating Half-Life Inherent Targeting Capability Inherent Targeting Capability Collagen-Derived and Biocompatible Collagen-Derived and Biocompatible Thermoresponsive and Injectable Thermoresponsive and Injectable RGD-Containing for Cell Adhesion RGD-Containing for Cell Adhesion Programmable Sequence and Stimuli-Responsive Programmable Sequence and Stimuli-Responsive Precise Response to Enzymes/pH Precise Response to Enzymes/pH Self-Assembling Nanofibers and Tubular Structures Self-Assembling Nanofibers and Tubular Structures Synergy of Natural Bioactivity and Synthetic Control Synergy of Natural Bioactivity and Synthetic Control Combines Long-Circulation (eg, PEG-like) Combines Long-Circulation (eg, PEG-like) Highly Customizable Functionality Highly Customizable Functionality Tunable Degradation and Release Kinetics Tunable Degradation and Release Kinetics Precise Control via Molecular Weight/Ratio Precise Control via Molecular Weight/Ratio FDA-Approved with Proven Safety FDA-Approved with Proven Safety Fe2⁺: Ferroptosis-driven cell clearance via ROS/GSH axis. Fe2⁺: Ferroptosis-driven cell clearance via ROS/GSH axis. Mg2⁺: Safe immunomodulation, anti-inflammatory, and anti-erosion. Mg2⁺: Safe immunomodulation, anti-inflammatory, and anti-erosion. Mn2⁺: Reverses hypoxia and reprograms the inflammatory microenvironment. Mn2⁺: Reverses hypoxia and reprograms the inflammatory microenvironment. MNPs: Multimodal theranostics MNPs: Multimodal theranostics AuNPs: Photothermal/chemodynamic therapy and immunomodulation for multimodal diagnosis and therapy. AuNPs: Photothermal/chemodynamic therapy and immunomodulation for multimodal diagnosis and therapy. High surface area, tunable pores, large drug-loading capacity. High surface area, tunable pores, large drug-loading capacity. Enable sustained, targeted delivery and imaging. Enable sustained, targeted delivery and imaging. Natural Polymeric Materials In the field of targeted therapy for rheumatoid arthritis (RA), self-assembling drug delivery systems based on natural polymeric materials offer distinct advantages. Derived from biological sources, these systems exhibit high biocompatibility, biodegradability, and inherent targeting and recognition capabilities. Through mild molecular interactions, they self-assemble into safe and efficient carriers, enabling precise drug delivery and intelligent release while significantly reducing toxic side effects. These materials primarily include polysaccharides, proteins, and peptides. Polysaccharides Polysaccharides are a class of macromolecular compounds widely distributed in nature, exhibiting pharmacological activities such as immune regulation and anticancer effects. Polysaccharides are formed by the polymerization of ten or more monosaccharide molecules via glycosidic bonds, possessing relatively large molecular weights. As polyhydroxy hydrophilic compounds, they can self-assemble through hydrogen bonding formed by their hydroxyl groups. Polysaccharides are natural macromolecules.134 Such as hyaluronic acid, chitosan, dextran, and cyclodextrin, which occupy an important position in drug delivery systems due to their excellent biocompatibility, degradability, and multifunctionality.135 They are widely used in self-assembling drug delivery systems for rheumatoid arthritis. They typically degrade naturally into non-toxic small molecules through metabolic pathways within the body (such as enzymatic hydrolysis), thereby avoiding the potential long-term toxicity accumulation associated with synthetic materials. Hyaluronic acid (HA),71–73 as a naturally occurring glycosaminoglycan, possesses significant immunomodulatory activity, the strength of which correlates with its molecular weight (MW).74 HA achieves CD44 targeting and smart drug delivery by forming nanomicelles/particles through hydrophobic interactions with hydrophobic drugs (curcumin, tripterygium wilfordii homofuranone, etc)., or by forming core-shell structures with host-guest pairing molecules. It also forms hydrogels through electrostatic interactions with charged drugs for sustained-release delivery within joint cavities. HA’s advantage lies in its high affinity for the CD44 receptor—which is overexpressed on RA synovial cells and activated immune cells—endowing HA with inherent targeting capability.75 HA-modified self-assembling carriers can precisely target synovial cells,76 especially at the site of inflammation, improving drug concentration and retention time within the joint.77 Effectively suppresses inflammatory responses.78 Chitosan,79,80 as a natural cationic polysaccharide, derives its core pharmacological effects from its exceptional mucosal adhesion and permeation-enhancing capabilities.81 It can bind to negatively charged mucosal surfaces via electrostatic interactions, prolonging drug retention time and reversibly opening tight junctions between epithelial cells. This significantly enhances the bioavailability of macromolecular drugs (such as insulin and protein peptides) while reducing the risk of enzymatic degradation.82 Chitosan utilizes its positive charge and mucosal affinity to form nano-micelles/particles with hydrophobic anti-inflammatory drugs, enhancing synovial penetration. It also binds with negatively charged nucleic acids/ peptides to regulate immunity, and forms chelated particles with metal ions to confer antibacterial and anti-inflammatory properties. It can also combine with hyaluronic acid and other agents to form hydrogel scaffolds, providing both targeted delivery and lubrication.83 Chitosan coating offers mucoadhesion, sustained release, and intrinsic anti-inflammation. In CS-coated nanocarriers for lornoxicam and leflunomide, CS synergizes with drugs to inhibit NF-κB, reduce TNFα/IL-6, achieve 77% and 48.68% edema inhibition, and improve liver function—acting beyond a mere carrier.84,85 Dextran is a homopolysaccharide composed of D-glucose units. As a natural polysaccharide,86 dextran finds extensive application in the medical field due to its advantages of high water solubility, excellent biocompatibility, and biodegradability. Dextran sulfate (DS), a naturally occurring anionic polysaccharide, exhibits outstanding biocompatibility, degradability, and a strong negative charge (Zeta potential −47.5 mV).87 Dextran forms nanocarriers by encapsulating poorly soluble drugs through hydrophobic interactions to enhance bioavailability. It binds to positively charged drugs/ nucleic acids through electrostatic self-assembly into hydrogels to suppress pro-inflammatory factors, and coordinates with metal ions to form nanoparticles for synergistic killing of diseased cells. Compared to dextran, dextran sulfate specifically inhibits P-selectin-mediated cell adhesion, effectively blocking inflammatory cell recruitment to joint tissues. Secondly, dextran sulfate itself possesses heparin-like anticoagulant activity and anti-inflammatory effects, enabling simultaneous drug delivery and intervention in thrombosis and the inflammatory cascade to achieve integrated “delivery-therapy” functionality.88 Cyclodextrins are cyclic oligosaccharides formed by glucose units linked via α-1,4-glycosidic bonds.89,90 Their truncated cone structure exhibits amphiphilic properties—hydrophilic externally and hydrophobic internally—enabling self-assembly with drugs or nucleic acids through host-guest inclusion, hydrogen bonding, and electrostatic interactions. This forms stable nanoparticles or hydrogels in aqueous solutions. Hydroxyl groups on the outer surface facilitate water solubility and enable interactions with negatively charged drugs or nucleic acids. The internal hydrophobic cavity significantly enhances the solubility and stability of hydrophobic drugs like curcumin and vinblastine through inclusion complexes, promoting their active targeting to inflammatory sites. Due to its excellent biocompatibility, degradability, low immunogenicity, and GRAS safety profile, cyclodextrin is widely used to improve the delivery of poorly soluble anti-inflammatory drugs.91 For example, hydrophobic-modified β-cyclodextrin (HA-β-CD) can encapsulate dexamethasone sodium phosphate (DSP) to form spherical nanoparticles (DSP-NPs) approximately 105 nm in size, achieving a release rate of 92% within 24 hours. This approach utilizes hydrophobic interactions to stabilize the nanostructure while enabling controlled drug release.92 Protein Category Protein assembly technology is advancing rapidly in the development of novel biomaterials,93 with its applications continually expanding.94 Gelatin,95 as a hydrolyzed product of collagen, is widely used in drug delivery and tissue engineering due to its excellent biocompatibility and degradability.96 Its thermoreversible gel properties are particularly suitable for microsphere preparation and drug delivery. Gelatin can form nanomicelles or particles with hydrophobic drugs like methotrexate and curcumin through hydrophobic interactions. Its positively charged amino groups enhance electrostatic adsorption to inflammatory synovial cells, improving synovial permeability. It can also self-assemble into nanoparticles with MMP-sensitive prodrugs via MMP-responsive covalent bonds, triggering smart drug release in the MMP-rich environment of RA synovium. Furthermore, it can form composite hydrogels with polysaccharides like hyaluronic acid or peptides through hydrogen bonding and electrostatic interactions, enabling sustained drug release, joint lubrication, and reduction of friction-induced damage. Albumin is the most abundant multifunctional protein in plasma.97 As a drug delivery system, it offers advantages such as excellent biocompatibility, degradability, low toxicity, and low immunogenicity.98 It forms nanoparticles with hydrophobic anti-inflammatory drugs such as dexamethasone through hydrophobic interactions, prolonging drug half-life and promoting trans-synovial capillary wall accumulation in inflamed joints. In RA therapy, albumin leverages its inherent biocompatibility and stability to form stable drug complexes, enhancing drug stability and prolonging circulation time. For instance, albumin-based nanomedicines (eg, MTX@HSA NMs) utilize albumin’s natural properties to achieve biomimetic targeted delivery.99 Peptides Peptide molecules are fundamental building blocks composed of two or more amino acids.100,101 Due to their exceptional biocompatibility and design flexibility, they have garnered significant attention in the field of nanomedicine delivery.102 To address issues such as poor stability and short half-life of natural peptides, they can self-assemble into diverse nanocarriers through multiple noncovalent interactions: forming nanomicelles or particles with hydrophobic drugs to enhance solubility; creating nanoparticles or hydrogels with negatively charged nucleic acids (eg, DNA, siRNA) via electrostatic interactions to protect and sustain-release gene therapeutics; or through hydrogen bonding/electrostatic interactions with polysaccharides and peptides (eg, hyaluronic acid) to construct composite hydrogels or scaffolds with combined anti-inflammatory, regenerative, and targeted lubrication functions.103 Additionally, through precise synthetic strategies such as solid-phase peptide synthesis, ring-opening polymerization, or recombinant expression, functionalized peptide-polymer conjugates or peptide amphiphiles can be prepared.104,105 These enable targeted drug delivery and controlled release through environmental stimuli like pH or enzymes.106 However, peptide systems still face challenges such as complex synthesis and purification, susceptibility to degradation in vivo, potential immunogenicity, and poor reproducibility in large-scale production. These factors limit their long-term application and clinical translation in chronic diseases like rheumatoid arthritis.107 Semi-Synthetic Materials Semi-synthetic materials integrate the biocompatibility of natural polymers with the tunability of synthetic polymers,71,108 enabling the construction of highly efficient nanoscale drug delivery systems through self-assembly.109 Such materials can self-assemble into various carriers—including nanoparticles, micelles, and microneedles—through noncovalent interactions such as hydrophobic forces, electrostatic forces, and hydrogen bonds with drugs like methotrexate and tripterygium wilfordii extract. This significantly enhances drug solubility and bioavailability. Simultaneously, they leverage the unique microenvironment of rheumatoid arthritis (RA) lesions—characterized by high reactive oxygen species (ROS), low pH, and elevated matrix metalloproteinase-2 (MMP-2)—to achieve passive targeting and stimulus-responsive controlled release. Their core advantage lies in precisely engineered functionality: using natural polysaccharides like hyaluronic acid (HA) and chitosan as scaffolds, they can be grafted with synthetic segments such as polyethylene glycol (PEG) and polycaprolactone (PCL) to form structurally defined amphiphilic block copolymers. For instance, in rheumatoid arthritis (RA) therapy, HA enables active targeting through its viscoelasticity, anti-inflammatory properties (eg, joint lubrication, inhibition of inflammatory infiltration and cytokine release), and ability to bind CD44 receptors. Meanwhile, PEG significantly prolongs drug half-life by forming a hydrophilic “cloud” shielding effect that reduces enzymatic degradation and immune clearance (eg, PEG-TRAIL exhibits approximately 13-fold longer half-life than native TRAIL).110 HA-PCT is an amphiphilic semi-synthetic material formed by grafting hydrophobic segments (PCT) onto a hyaluronic acid (HA) backbone. It specifically binds to the CD44 receptor, highly expressed in synovial tissue, and utilizes its hydrophobic PCT segments to efficiently encapsulate poorly soluble drugs or active components from traditional Chinese medicine, such as Tripterygium wilfordii homofuranoside. This approach enhances solubility and loading efficiency while leveraging the nano effect to improve drug penetration and distribution within the dense synovial tissue. Synthetic Materials Synthetic materials primarily rely on hydrophobic interactions and synergistic driving forces between hydrophilic and hydrophobic segments in amphiphilic block copolymers. These materials spontaneously self-assemble into core-shell structured nanomicelles or nanoparticles in aqueous phases or serve as building blocks embedded within hydrogels. The hydrophobic segments (eg, PLA, PCL) form the core to encapsulate poorly soluble drugs, while hydrophilic segments (eg, PEG, PDMA) constitute the shell to enhance colloidal stability, prolong circulation, and confer environmental responsiveness (eg, pH-triggered drug release). This approach achieves efficient drug loading, controlled release, and biological safety. Typical systems like PLGA enable precise degradation rate control through molecular weight adjustment and lactic acid/glycolic acid ratio tuning, achieving sustained drug release. Combining with PEG further optimizes release kinetics and enhances retention at target sites.111 The hydrophilic mPEG in mPEG-PLA confers “invisibility” properties to prolong circulation time, while the hydrophobic PLA core efficiently encapsulates poorly soluble drugs such as methotrexate; PCL-PEG-PCL leverages PCL’s degradable rigidity and PEG’s extended circulation and biocompatibility to self-assemble into stable nanomicelles or hydrogel units, effectively enhancing drug solubility and stability while reducing long-term accumulation risks; PLGA-b-PDMA combines the hydrophobic degradability of PLGA with the pH-responsive hydrophilicity of PDMA. It undergoes protonation in acidic inflammatory microenvironments to trigger drug release and enhance cellular uptake, achieving targeted delivery and smart drug release at the lesion site. This ensures the comprehensive efficacy and safety of the delivery system. Inorganic Materials In rheumatoid arthritis (RA) therapy, inorganic materials primarily encompass two categories: inorganic nanoparticles and metal ions. Inorganic nanoparticles (such as magnetic nanoparticles and gold nanoparticles) can self-assemble into structurally controllable delivery systems, integrating superior targeting capabilities, imaging functions, and therapeutic properties to achieve precise drug delivery and multi-modal synergistic treatment. Metal ions (eg, iron, magnesium, and manganese ions) self-assemble into functional materials that exert multiple effects—including immunomodulation, antioxidant activity, and metabolic regulation—in response to microenvironmental cues. Metal Ions Iron ions (Fe2⁺/Fe32⁺) serve as the catalytic core in treatment, triggering the Fenton reaction within the acidic,112–114 hydrogen peroxide (H2O2)-rich microenvironment of rheumatoid arthritis (RA). This generates highly toxic hydroxyl radicals (·OH), which directly oxidize and damage the membranes and mitochondria of pro-inflammatory cells. O2), generating highly toxic hydroxyl radicals (·OH) that directly oxidatively damage pro-inflammatory cell membranes and mitochondria. Concurrently, Fe3⁺ undergoes redox reactions with glutathione (GSH), depleting GSH reserves and weakening cellular antioxidant defenses, thereby amplifying reactive oxygen species (ROS) toxicity. Furthermore, iron ion accumulation induces ferroptosis by activating lipoxygenases to promote lipid peroxidation while inhibiting glutathione peroxidase 4 (GPX4) activity. This leads to lipid peroxide accumulation and cell membrane rupture, selectively eliminating activated macrophages and fibroblast-like synovial cells.115 Fe2⁺/Fe3⁺ commonly serve as core components or slow-release ions in magnetic nanoparticles (eg, Fe3O4), where they are encapsulated and integrated into nanocarriers. Within the RA lesion microenvironment, they simultaneously induce ROS generation, GSH depletion, and ferroptosis, establishing a “catalytic-killing” multistage anti-inflammatory mechanism encapsulation into nanocarriers. Within the RA lesion microenvironment, they simultaneously induce ROS generation, GSH depletion, and ferroptosis, establishing a “catalytic-killing” multistage anti-inflammatory mechanism. Such magnetic nanosystems can also load drugs like methotrexate (MTX), enabling targeted accumulation and controlled release (sustained for 6–7 days) via external magnetic field guidance, significantly enhancing drug specificity and overcoming non-specific distribution issues.116 Magnesium ions (Mg2⁺) act as natural immune modulators in rheumatoid arthritis (RA) treatment. They effectively alleviate joint inflammation and bone erosion by inhibiting the release of inflammatory mediators such as TNF-α and IL-1β, regulating T-cell function, and suppressing osteoclast activity.117 Given that hypomagnesemia frequently accompanies RA, supplementing Mg2⁺ serves a dual purpose of correcting metabolic disorders and treating the disease. Its high biological safety and well-defined metabolic pathways enable integration with hydrogel or nanomaterial pore/coordination structures to form sustained-release magnesium ion systems. Leveraging the controlled release properties of self-assembly, these systems deliver sustained magnesium ion release at inflammatory sites, thereby exerting long-term immunomodulatory effects and establishing an “immunomodulation-sustained release” functional factor system. Manganese ions (Mn2⁺) exert multifunctional synergistic effects in rheumatoid arthritis (RA) treatment through manganese-based nanomaterials (eg, MnO2, Mn2O4) by responding to the RA acidic and reactive oxygen species (ROS)-rich microenvironment. Mn3O4) exert multifunctional synergistic effects in rheumatoid arthritis (RA) treatment. This mechanism relies on their responsiveness to the acidic and reactive oxygen species (ROS)-rich RA microenvironment: MnO2 nanoparticles decompose under acidic conditions, consuming excess H2O2 and generating oxygen in situ to alleviate joint hypoxia. Concurrently, they promote macrophage polarization from pro-inflammatory M1 to anti-inflammatory M2 types, thereby reshaping the inflammatory microenvironment.118 Mn2⁺ often self-assembles with polysaccharides or drug molecules, for example, in the form of MnO2 or Mn3O4 nanocomposites, through electrostatic interactions and hydrogen bonding. At the inflammatory lesion, these Mn-based assemblies can respond to local microenvironmental signals (eg, low pH, high H2O2) to achieve targeted drug delivery, scavenge reactive oxygen species (ROS), and generate oxygen in situ, thereby constructing a core “microenvironment‑modulation and synergistic therapy” system. Metal Nanoparticles Magnetic nanoparticles (MNPs) are a class of nanomaterials that integrate drug delivery, imaging, diagnostics, and targeting functions.119–121 Their advantages stem from their ultra-small size, inherent superparamagnetism, excellent biocompatibility, flexible surface chemistry, and low systemic toxicity.122 These particles typically feature a superparamagnetic iron core. After functionalization with PEG or PEI, they can load anti-rheumatoid arthritis (RA) drugs, enabling targeted joint delivery under an external magnetic field to significantly reduce systemic toxicity. The iron core itself serves as a T1/T2 weighted magnetic resonance imaging (MRI) contrast agent, enabling precise visualization of inflamed synovium and enhancing diagnostic accuracy. Under alternating magnetic fields, MNPs generate controllable thermal effects for magnetotherapeutic ablation of abnormally proliferated synovial tissue while promoting drug accumulation at the joint site, thereby establishing a multifunctional “magnetic targeting-imaging-therapy” integrated diagnostic and therapeutic platform.123 Gold nanoparticles (AuNPs) have emerged as ideal carriers for achieving photothermal and immunomodulation in rheumatoid arthritis (RA) self-assembly systems due to their exceptional optical properties, surface plasmon resonance (SPR) effects, and controllable particle sizes. By adjusting reaction conditions, AuNPs with diverse morphologies—including spherical, rod-shaped, and double-cone forms—can be synthesized. After functionalization via thiol-gold chemistry, these particles self-assemble into units capable of both photothermal and chemodynamic therapy (CDT): Under near-infrared irradiation, heat is generated via the SPR effect. Concurrently, peroxidase/catalase-like activity catalyzes the formation of highly toxic hydroxyl radicals (·OH) within the RA microenvironment rich in reactive oxygen species (ROS), enabling synergistic photothermal-chemical kinetic therapy.124 Additionally, AuNPs can be functionalized with targeted ligands such as folic acid to achieve precise delivery to joint sites. Leveraging their straightforward synthesis and modification methods, they enable the construction of multifunctional phototherapeutic platforms integrating photothermal, catalytic, and targeted capabilities.125 Palladium nanoparticles (Pd NPs), as inorganic nanomaterials, exhibit outstanding photothermal conversion efficiency and excellent biocompatibility. Under near-infrared irradiation, they can efficiently generate localized heat for precise thermal ablation therapy. Additionally, their size and morphology are tunable, facilitating easy conjugation with functional molecules or carriers (such as hyaluronic acid, HA) to achieve targeted delivery and integrated multimodal therapy. For instance, the Pd@Se-HA hybrid system self-assembles into a core-shell structure via electrostatic/coordination interactions. The Pd core mediates near-infrared photothermal effects, while the outer Se or HA layer synergistically provides antioxidant or drug-loading functions. This forms a “photothermal-triggered microenvironment regulation” synergistic therapeutic core, enabling efficient, minimally invasive local interventions that simultaneously deliver on-demand treatment and microenvironment modulation in inflammatory diseases like rheumatoid arthritis. Inorganic-Organic Hybrid Materials Metal-organic frameworks (MOFs) are porous crystalline “molecular buildings” self-assembled through coordination bonds between metal ions or clusters and organic ligands.126–129 With their high specific surface area, tunable pore sizes, and excellent biocompatibility, MOFs serve as nanocarriers capable of physically encapsulating or coordinatively loading various anti-rheumatoid arthritis (RA) drugs such as methotrexate (MTX) and TNF-α siRNA.130 The drug delivery system composed of MOFs responds to the acidic and highly reactive oxygen species (ROS) microenvironment of RA lesions, enabling dual pH/ROS-responsive drug release. It simultaneously exerts multiple functions, including anti-inflammation, ROS scavenging, and immune modulation, thereby enhancing therapeutic efficacy while reducing systemic toxicity. Furthermore, drug release can be precisely controlled through framework degradation or host-guest interactions131 and utilize surface engineering (such as PEGylation) to enhance stability and prevent burst release.132 For example, covalently linking MTX to tannic acid (TA) followed by self-assembly with Fe3⁺ forms MTX-TA/Fe3⁺ MOF, achieving a high drug loading capacity of approximately 45% and sustained, low-leakage drug release.133 Characterization of Self-Assembled Drug Delivery Systems The characterization of self-assembling delivery systems (SADDS) should follow a logical sequence: “basic physicochemical properties—assembly behavior—drug-loading capacity—morphology and structure—functional performance—stability”. Differentiated strategies should be adopted for various carriers, such as nanoparticles, micelles, hydrogels, and microneedles, while also addressing common technical bottlenecks.136–138 In terms of basic physical and chemical properties, dynamic light scattering (DLS) is based on the Brownian motion of suspended particles: the smaller the particles, the faster they diffuse, resulting in a higher frequency of fluctuations in the scattered light intensity. By analyzing time-dependent functions and applying the Stokes-Einstein equation, the hydrodynamic diameter can be calculated. This is a core method for determining the particle size of nanoparticles and micelles, as well as the polydispersity index (PDI), which is typically required to be 0.3 to confirm the monodispersity of the system. Zeta potential is measured using laser Doppler microelectrophoresis and reflects the net charge on the nanoparticle surface; an absolute value >30 mV indicates that the electrostatic repulsion between particles is sufficient to overcome van der Waals forces, thereby ensuring good colloidal stability. For hydrogels, a rheometer is used to characterize the storage modulus (G′) and loss modulus (G″), where G′ reflects the material’s elastic behavior (similar to a solid) and G″ reflects its viscous behavior (similar to a liquid); a value of G′ > G″ indicates the formation of a stable three-dimensional network structure. Concurrently, shear thinning and self-healing properties are determined using rotational or oscillatory modes. For microneedles, a texture analyzer is used to measure the breaking force and Young’s modulus to ensure they possess sufficient mechanical strength to penetrate the stratum corneum (typically requiring a breaking force of >0.1 N per needle). Studies of assembly behavior focus on the formation mechanisms and thermodynamic stability of self-assembled structures. The critical micelle concentration (CMC) or critical aggregation concentration (CAC) is a key parameter for evaluating the dilution stability of micelles and nanoparticles, and is commonly determined using the pyrene fluorescence probe method.139 The mechanism is as follows: due to its extremely low solubility in the aqueous phase, pyrene preferentially distributes into the hydrophobic microenvironment; when self-assemblies form, pyrene enters the hydrophobic core, and the ratio of the first vibrational peak (I1, approximately 373 nm) to the third vibrational peak (I3, approximately 384 nm) in its fluorescence spectrum (I1/I3) decreases significantly as the polarity of the hydrophobic environment decreases. The CMC/CAC is calculated using the inflection point of the ratio-concentration curve. A lower value indicates that the self-assembled structure is less prone to dilution and dissociation in the bloodstream. For hydrogels, assembly behavior is characterized by measurements of gelation time, swelling ratio, and phase transition temperature (LCST or UCST). The swelling ratio is determined based on the Flory-Rehner theory and calculated using a gravimetric method; the phase transition temperature is determined via rheological temperature scanning or UV spectrophotometry (at the point of sudden change in transmittance). The assembly behavior of microneedles primarily focuses on tip formation and the uniformity of drug distribution within the needle body, and is commonly evaluated using micro-Raman spectroscopy (based on differences in molecular vibrational energy levels) or fluorescence imaging. Characterization of drug-loading performance is independent of assembly behavior and focuses on evaluating drug loading efficiency and state of existence. Encapsulation efficiency (EE%) and drug loading (DL%) are determined via HPLC or UV spectrophotometry (based on the Lambert-Beer law) after separating free drug by centrifugation or ultrafiltration; typically, an EE% > 80% is required to reduce the risk of toxicity from free drug. Common challenges exist across different carrier types: the drug loading capacity of liposomes and polymeric nanoparticles is often limited by core volume (typically 10%), whereas carrier-free nanoparticles can achieve nearly 100% drug loading through direct co-assembly of drug molecules (via hydrophobic interactions, π-π stacking, etc)., but suffer from poor physical stability. The drug loading capacity of hydrogels depends on the cross-linking density and hydrophilicity of the network; hydrophobic drugs require the use of cyclodextrins (via hydrophobic cavity inclusion) or pre-encapsulation in nanocrystals. Determining the crystalline state of the drug and drug-carrier interactions requires the combined use of multiple techniques: Differential Scanning Calorimetry (DSC), based on the principle that substances absorb or release heat during phase transitions, where the disappearance or significant weakening of characteristic melting peaks indicates a transition from a crystalline state to an amorphous molecular dispersion; X-ray Diffraction (XRD), based on Bragg’s law, where the disappearance of crystalline diffraction peaks similarly confirms amorphization; Fourier-transform infrared spectroscopy (FTIR), based on molecular vibrational energy level transitions, assesses the formation of intermolecular interactions such as hydrogen bonding and hydrophobic interactions through the shift, broadening, or disappearance of characteristic absorption peaks. Morphology and structure were examined using transmission electron microscopy (TEM, which utilizes an electron beam to penetrate ultrathin samples and generates images based on amplitude contrast), scanning electron microscopy (SEM, which detects secondary electron signals to reveal three-dimensional surface topography), and atomic force microscopy (AFM, which generates images based on the interaction between the probe and the surface atoms of the sample).140 TEM can reveal the internal core-shell structures of liposomes, micelles, and inorganic nanoparticles; SEM provides detailed images of particle surfaces; AFM can directly measure the height and surface topography of soft structures (such as hydrogel networks and lipid bilayers) in their hydrated state in solution; and the morphology of microneedles is characterized using stereomicroscopy and laser confocal microscopy (based on the principle of optical sectioning). Functional performance characterization focuses on in vitro release and smart response. Release kinetics were determined using the dialysis bag method or the Franz diffusion cell, and fitted using zero-order, first-order, Higuchi, or Ritger-Peppas models.141 For microneedles, it is also necessary to examine their in vitro transdermal penetration depth and rate, which are commonly evaluated using a Franz diffusion cell in conjunction with an ex 6.0–6.5, containing H2O2 or MMP substrates) to prevent drug leakage into non-target tissues. In terms of stability, all SADDS formulations must be evaluated for trends in particle size and zeta potential over time in physiologically relevant media such as Phosphate-Buffered Saline (PBS) and serum—an increase in particle size or PDI indicates particle aggregation (driven by Ostwald ripening resulting from surface energy minimization), while a decrease in the absolute value of the zeta potential suggests surface charge shielding or coating detachment. Accelerated stability testing (40°C, 55°C, high humidity, light exposure) predicts long-term storage stability based on the Arrhenius equation. Batch-to-batch consistency is a key bottleneck limiting the large-scale production of self-assembling systems; however, continuous microfluidic technology can significantly reduce batch-to-batch variability by precisely controlling temperature, flow rate, and mixing efficiency, utilizing the principle of diffusion mixing under laminar flow conditions. Applications of Self-Assembling Drug Delivery Systems in Rheumatoid Arthritis The core of self-assembled drug delivery systems in the treatment of rheumatoid arthritis (RA) lies in achieving precise drug targeting and controlled release, thereby addressing the issues of insufficient targeting and significant systemic side effects associated with traditional treatments. These strategies are primarily divided into two categories: drug-based self-assembly systems (such as co-assembly of active ingredients from traditional Chinese medicine), which can enhance the solubility and drug-loading capacity of hydrophobic drugs; and carrier-based self-assembly systems (such as polymeric nanoparticles and hydrogels). Different types of carriers offer distinct advantages in terms of structure, drug loading, drug delivery, and targeting: nanoparticles and micelles are suitable for systemic targeting and controlled release, while hydrogels and microneedle systems are better suited for local, sustained-release drug delivery (Figure 3). Application of Self-Assembling Drug Delivery Systems in Rheumatoid Arthritis. Applications of Carrier-Free Self-Assembling Delivery Systems in RA Carrier-free self-assembling drug delivery systems do not require the introduction of exogenous carriers; instead, they rely solely on the drug molecules themselves or their non-covalent interactions with a small number of amphiphilic molecules to directly assemble into nanostructures or hydrogels. This approach avoids the immunogenicity, degradation residues, and in vivo accumulation toxicity that may be associated with traditional carriers. In this system, the drug serves as both the active ingredient and a structural building block, offering high drug-loading capacity and resistance to rapid release. This “carrier-free” strategy significantly enhances the system’s biosafety while simplifying the manufacturing process and reducing costs.142 These primarily include two categories: small-molecule drug self-assembly systems, which use compounds such as garcinic acid and curcumin as building blocks and self-assemble via non-covalent interactions to improve drug solubility and stability; some of these systems possess pH-responsive drug release capabilities, enhancing drug retention at the site of action and oral bioavailability; Bionic self-assembly systems, which enhance biocompatibility and reduce immunogenicity through cell membrane encapsulation, and achieve smart drug release in response to the tumor microenvironment (eg, acidic pH, high MMP levels). These systems enhance drug accumulation and penetration at inflammatory sites while avoiding material toxicity (Table 2). Table 2Applications of Carrier-Free Self-Assembling Drug Delivery Systems in Rheumatoid ArthritisTypeStructural UnitSelf-Assembly Driving ForceKey Physical and Chemical CharacterizationEffectiveness of Drug TherapyReferencesGBA2 NPsCurcumin dimer (GBA2)Hydrogen bonds, hydrophobic interactionsDL: 85.78; zeta: −31.2 mV; PDI: 0.13In Vitro Activity: IC50↓ (2.531 μM)In Vivo Efficacy (CIA Model): Swelling↓ + BMD↑Inflammation↓ + Toxicity↓[143]2-DG/Cur NPs2-Deoxy-D-glucose (2-DG), Curcumin (Cur)Hydrogen bonds, hydrophobic interactionsZeta: −15.3 mV, DL: 2-DG99.8%, Cur 0.2%In Vivo Efficacy (CIA Model): Joint score and paw thickness↓ (~50%)Pro-inflammatory factors↓ (>60%, p < 0.001)Glycolysis markers↓ (~70%)Hepatotoxicity↓[144]OLA-Cur NPsOleanolic acid (OLA), Curcumin (Cur)Hydrogen bonding, hydrophobic interactions, π-π interactionsPDI: 0.21, Zeta: −6.1 mV, OLA: Cur 5:2In vitro anti-inflammatory activity: TNF-α↓, IL-6↓, IL-1β↓ (dose-dependent); IL-10↑ (~20%)Oxidative stress markers↓ (Nrf2/HO-1 pathway) in RASFs[145]PGA@Cel NPsGlycyrrhetinic acid (GA), Tripterygium wilfordii homofubic acid (Cel)Hydrogen bonds, π-π stacking, hydrophobic interactions, and electrostatic interactionsDL: Cel 4.5%, EE: 95%In Vivo Efficacy (AIA Rat Model): Arthritis index↓ (p < 0.01)Claw swelling↓ (~50%)Pro-inflammatory factors↓ (>60%)Joint pathology↓ + Cartilage erosion↓Hepatotoxicity↓and Nephrotoxicity↓[146]S-G HydrogelVinblastine (SIN), Glycyrrhetic acid (GA)Electrostatic forces, hydrogen bondingZeta: −39.7 mVIn Vivo Efficacy (AIA Rat Model): Joint diameter↓ (~50%) + Arthritis index↓Pro-inflammatory factors↓ (>60%)Cartilage protection↑ + Inflammation scores↓Hepatotoxicity↓ and Nephrotoxicity↓[147]HA-RM-Cel-BRHyaluronic acid (HA), Red blood cell membrane (RM), Celastrol (Cel), Bilirubin (BR)π-π stacking, hydrogen bondingCelastrol and bilirubin mass ratio 1:20In Vivo Efficacy (RA Rat Model): Joint swelling↓ (~60%) + Arthritis scores↓Bone erosion↓ (Micro-CT confirmed)TNF-α↓, IL-6↓Mechanism: M2 polarization↑Hepatotoxicity↓[148]BMC Nano SystemsBovine serum albumin (BSA), Methotrexate (MTX), Phototherapy agent CylHydrogen bondingPDI: 13±0.015; Zeta: −17.13±0.11 mVIn Vivo Efficacy (CIA Mouse Model): Joint diameter↓ (~50%)Pro-inflammatory factors↓ (>60%) + IL-10↑Bone destruction↓Hepatotoxicity↓ and Nephrotoxicity↓[149]M-EHPSEGCG, histidine (His), PBAP, TNF-a-RNA, M1 macrophage membrane (M1m)Hydrogen bonding, electrostatic forces, hydrophobic interactions-In Vivo Efficacy (CIA Mouse Model): Joint diameter↓ (~50%)Pro-inflammatory factors↓ (>60%) + IL-10↑Bone destruction↓Hepatotoxicity↓ and Nephrotoxicity↓[150]Abbreviations: NPs, nanoparticles; PDI, polydispersity index; EE, encapsulation efficiency; DL, drug loading; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; RA, rheumatoid arthritis; BMD, bone mineral density; TNF-α, tumor necrosis factor-alpha; IL, interleukin; IC50, half-maximal inhibitory concentration; RASFs, rheumatoid arthritis synovial fibroblasts; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase-1; EGCG, epigallocatechin-3-gallate; PBAP, phenylboronic acid pinacol ester; BSA, bovine serum albumin; MTX, methotrexate; ↑, increase; ↓, decrease; →, direction of action/process; >, greater than; <, less than. Applications of Carrier-Free Self-Assembling Drug Delivery Systems in Rheumatoid Arthritis IC50↓ (2.531 μM) IC50↓ (2.531 μM) Swelling↓ + BMD↑ Swelling↓ + BMD↑ Joint score and paw thickness↓ (~50%) Joint score and paw thickness↓ (~50%) Pro-inflammatory factors↓ (>60%, p < 0.001) Pro-inflammatory factors↓ (>60%, p < 0.001) Glycolysis markers↓ (~70%) Glycolysis markers↓ (~70%) TNF-α↓, IL-6↓, IL-1β↓ (dose-dependent); IL-10↑ (~20%) TNF-α↓, IL-6↓, IL-1β↓ (dose-dependent); IL-10↑ (~20%) Arthritis index↓ (p < 0.01) Arthritis index↓ (p < 0.01) Claw swelling↓ (~50%) Claw swelling↓ (~50%) Pro-inflammatory factors↓ (>60%) Pro-inflammatory factors↓ (>60%) Joint pathology↓ + Cartilage erosion↓ Joint pathology↓ + Cartilage erosion↓ Joint diameter↓ (~50%) + Arthritis index↓ Joint diameter↓ (~50%) + Arthritis index↓ Pro-inflammatory factors↓ (>60%) Pro-inflammatory factors↓ (>60%) Cartilage protection↑ + Inflammation scores↓ Cartilage protection↑ + Inflammation scores↓ Joint swelling↓ (~60%) + Arthritis scores↓ Joint swelling↓ (~60%) + Arthritis scores↓ Bone erosion↓ (Micro-CT confirmed) Bone erosion↓ (Micro-CT confirmed) TNF-α↓, IL-6↓ TNF-α↓, IL-6↓ Mechanism: M2 polarization↑ Mechanism: M2 polarization↑ Joint diameter↓ (~50%) Joint diameter↓ (~50%) Pro-inflammatory factors↓ (>60%) + IL-10↑ Pro-inflammatory factors↓ (>60%) + IL-10↑ Bone destruction↓ Bone destruction↓ Joint diameter↓ (~50%) Joint diameter↓ (~50%) Pro-inflammatory factors↓ (>60%) + IL-10↑ Pro-inflammatory factors↓ (>60%) + IL-10↑ Bone destruction↓ Bone destruction↓ Abbreviations: NPs, nanoparticles; PDI, polydispersity index; EE, encapsulation efficiency; DL, drug loading; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; RA, rheumatoid arthritis; BMD, bone mineral density; TNF-α, tumor necrosis factor-alpha; IL, interleukin; IC50, half-maximal inhibitory concentration; RASFs, rheumatoid arthritis synovial fibroblasts; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase-1; EGCG, epigallocatechin-3-gallate; PBAP, phenylboronic acid pinacol ester; BSA, bovine serum albumin; MTX, methotrexate; ↑, increase; ↓, decrease; →, direction of action/process; >, greater than; <, less than. Self-Assembly Systems of Carrier-Free Small-Molecule Pure Drugs Despite garcinic acid’s (GBA) anti-inflammatory properties mediated by the PI3K/0-Akt pathway,151 its therapeutic utility is compromised by poor solubility and low bioavailability. To circumvent these limitations, Liu et al143 synthesized GBA2 through dimerization and subsequently formed self-assembled nanoparticles (GBA2/NPs) exhibiting an impressive drug loading capacity of up to 85.78%, thereby realizing an integrated “drug-as-carrier” design. These nanoparticles leverage the ELVIS effect for joint targeting, inducing apoptosis in macrophages and osteoclasts while simultaneously inhibiting the NF-κB/NLRP3 pathways, conferring potent anti-inflammatory and bone-protective effects. Curcumin, characterized by its low toxicity and high safety profile, is amenable to long-term or combination therapies and demonstrates multifaceted biological activities, including anti-inflammatory and antioxidant functions.152 The Stenzel team discovered that fructose can induce self-assembly into ordered nanocapsules measuring 100–150 nm.153 Chen et al144 developed 2-Deoxy-D-glucose (2-DG) and curcumin (Cur) co-encapsulated nanoparticles (2-DG/Cur NPs), wherein 2-DG targets GLUT1 to inhibit HIF-1α, a critical regulator of glycolysis, while Cur concurrently inhibits the NF-κB pathway. This dual-action strategy effectively suppresses inflammatory cells and signaling cascades. Further advancements by Li et al145 involved the co-assembly of oleanolic acid-curcumin (OLA-Cur) into nanoparticles, achieving a cumulative release rate of 89.7 ± 3.9% over 144 hours at pH 7.8. These nanocarriers demonstrated efficacy in inhibiting LPS-induced pro-inflammatory factors, augmenting IL-10 secretion, and providing antioxidant protection to cartilage. Addressing curcumin’s inherent low water solubility and bioavailability challenges, glycyrrhizic acid (GA), with its favorable water solubility, metabolic stability, and prolonged therapeutic duration, has emerged as a promising agent for rheumatoid arthritis (RA) treatment.154 Zhang et al146 successfully loaded scutellarin onto polygalacturonic acid (PGA), yielding an encapsulation efficiency of 95%. This formulation markedly reduced the arthritis index from 4 points to nearly 0 points (p < 0.01), decreased paw thickness by 50%, and lowered inflammatory cytokine levels by over 60%. In contrast to nanoparticles primarily engineered for targeted delivery, self-assembled hydrogels offer dual administration routes (injection and oral) and exhibit heat-induced in situ gelation along with substantial drug-loading capacity (Figure 4). Jiang et al147 exploited the electrostatic interactions and hydrogen bonds between sinapine (SIN) and glycyrrhetic acid (GA) to fabricate a thermoreversible S–G hydrogel under physiological conditions. This hydrogel can be administered via local intra-articular injection, functioning as a sustained-release depot, or orally, approximately doubling the peak plasma concentration of sinapine and thus substantially enhancing its bioavailability. This approach offers advantages in therapeutic longevity and dosing flexibility. In vivo anti-rheumaticeffciency of NPs. (A) Schematictherapy depiction of NPs inAIA rat models. (B) Arthritis index. (C) Secondary paw thickness (mm) and (D) paw swelling after treatment with NPs for the treatment period. The serum levels of anti-infammatory (E–G) TNF-α, IL-1β, and IL-6, and anti-infammatory (H) TGF-β1 after treatment. (I) H&E and Masson staining of rat ankles after treatment. (J) Changes in body weight. (K) Thymus and (L) spleen index of after treatment with NPs. Data are presented as the mean ±SD (n =5), *p <0.05, **p <0.01, ***p <0.001, and ****p <0.0001. Reprinted from ref146 with permission. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). Carrier-Free Biomimetic Self-Assembly Systems Su et al148 developed an HA-RM-Cel-BR drug delivery system. Cel and BR self-assemble into a nano-core coated with HA-modified red blood cell membranes. BR triggers ROS-responsive Cel release, Cel inhibits the cGAS-STING pathway, while BR scavenges radicals, synergistically promoting M2 macrophage polarization. In AIA rats, NPs effectively alleviate arthritis, reduce pro-inflammatory cytokines, protect joint tissues, and exhibit favorable biosafety. (Figure 5) Xue et al149 engineered a BMC system through self-assembly of bovine serum albumin (BSA), methotrexate (MTX), and the photosensitizer Cyl. This system integrates active targeting and light-controlled drug delivery functionalities: endogenous BSA demonstrates a natural affinity for SPARC protein, which is highly expressed in synovial tissue, whereas MTX targets the folate receptor FRβ. Light irradiation concurrently elicits the photothermal and photodynamic effects of Cyl, leading to the ablation of M1-type macrophages and precise control over MTX release. Yang et al150 designed core-shell nanoparticles that were self-assembled using the natural polyphenol EGCG, histidine (His), the ROS-sensitive molecule PBAP, and siRNA, and were coated with M1 macrophage membrane (M1m) to achieve homogeneous targeting and efficient accumulation at the lesion site. In the inflammatory microenvironment, PBAP degrades into boronic acid, disrupting hydrophobic interactions and hydrogen bonds, thereby promoting the synergistic release of siRNA and EGCG: siRNA silences TNF-α expression, while EGCG efficiently scavenges reactive oxygen species (DPPH scavenging rate > 80%); together, they synergistically remodel the joint immune microenvironment. Following intravenous administration (siRNA 1.5 mg/kg), joint inflammation scores decreased by 50%, inflammatory cytokine levels dropped by 60%, and particle size increased from the initial value to 587 nm, confirming the system’s excellent ROS responsiveness. Therapeutic effect of HA-RM-Cel-BR on RA in vivo. (a) Establishment and treatment protocol of RA rat model. (b) Degree of toe swelling in difer-ent treatment groups. (c and f) Temperatures of inflamed paws measured by thermal imaging. (d) Arthritis function score in different treatment groups. (e) Photographs of inflamed joints in different treatment groups. (g) Micro-computed tomography (micro-CT) analysis of bone tissues in different treatment groups. Data are presented as mean±SD (n=6). *P<0.05, **P<0.01, and ***P<0.001Reprinted from ref148 with permission. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). Applications of Carrier-Based Self-Assembling Drug Delivery in Rheumatoid Arthritis Compared to free-floating drugs without carriers, self-assembled drug delivery systems constructed from various materials offer significant advantages in terms of enhancing drug concentration at the site of action, prolonging the duration of action, reducing systemic toxicity, and improving patient compliance, thanks to their structural design flexibility, environmental responsiveness, and targeting capabilities. Amphiphilic polymers can self-assemble to form nanoparticles and micelles.155 With a small particle size and a flexible structure, they can penetrate dense glial matrix to achieve efficient penetration of the lesion site and targeted delivery.156 Self-assembled hydrogelstypically feature injectability, structural stability, high drug-loading capacity, and sustained release, and support both oral and topical administration, thereby significantly improving drug bioavailability. Microneedle arrays made of soluble or degradable materials rapidly dissolve after penetrating the skin, converting mechanical energy into the driving force for drug release, thereby enabling minimally invasive and precise local delivery. Self-Assembling Nanoparticle Delivery System Zhao et al157 the bilirubin-polyethylene glycol (BR-mPEG) self-assembled nanoparticles (BRNP) loaded with tripterygium lactone (CLT). Excess ROS at the inflammation site triggers drug release, while BR scavenges free radicals, forming a self-regulating “therapeutic–antioxidant” cycle. Schluep et al158 developed CDP-MP, which utilizes the self-assembly of α-methylprednisolone (MP) and cyclodextrin polymers (CDP) via host–guest self-assembly of MP and cyclodextrin polymer. Plasma esterases trigger sustained release (t1/2 ≈ 19 h). EPR-mediated joint targeting reduces systemic toxicity. Zhang et al90 synthetic polyamide (PA) copolymer self-assembled nanoparticles (PAT) loaded with tripterygiol (TP) also utilize the EPR-mediated passive accumulation enables slow TP release, suppressing inflammatory factors and alleviating synovitis, cartilage damage, and osteoclast activation. In RA models, PAT reduced paw swelling and temperature, improved function scores, and micro-CT confirmed bone protection (Figure 6); Liu et al159 designed PLGA–b–PDMA amphiphilic copolymer self-assembled into cationic nanoparticles (cNPs). An MMP-2-sensitive peptide removes the PEG shield, exposing the cationic surface for enhanced cellular uptake—transitioning from “systemic stealth” to “local activation”—and achieving 100% survival in a mouse model. Li et al160 designed a self-assembling system that was developed using ethylene glycol-chitosan (GC) and stearic acid (SA) to form the amphiphilic copolymer GC-SA, which self-assembles to load methotrexate (MTX), forming MTX-GC-SA nanoparticles. Beyond EPR-mediated delivery, the system actively inhibits NF-κB, reducing pro-inflammatory cytokine production. Zewail et al161 developed a PG-based propososome that reduces interfacial tension, improves membrane fluidity, and optimizes lipid bilayer packing. Polyglycol (PG) enhances the solubility of BCS II/IV drugs and enables self-assembly. After chitosan/hyaluronic acid coating, the carrier achieved 178.7 nm size, –50.46 mV zeta potential, 94.12% encapsulation efficiency, and 65.2% release at 84 h. In RA rats, it reduced foot edema by 39.24%, lowered TNF-α/IL-1β by 3.47- and 4.75-fold, and upregulated Nrf2 by 2.73-fold. Both TP and PaT reduce bone erosion in TNFα-Tg mice. (A) longitudinal sections of 3-dimensional reconstructed ankle and knee joints by micro-cT show decreased bone erosion in TP- and PaT-treated mice. (B) Quantitation of bone volume of astragalus and patella. Values are the mean ± sD of 7–10 legs per group. *P, 0.05, compared with PBs-treated group. Reprinted from ref90 with permission. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). Abbreviations: micro-cT, microcomputed tomography; WT, wild type; TNFα-Tg, tumor necrosis factor α transgenic; PBs, phosphate buffer saline; Pa, poly-γ-glutamic acid-grafted di-tert-butyl l-aspartate hydrochloride; TP, triptolide; PaT, TP-loaded poly-γ-glutamic acid-grafted di-tert-butyl l-aspartate hydrochloride. Gold nanoparticles (GNPs) form a wine-red solution and possess anti-inflammatory properties; due to their excellent physicochemical properties, GNPs show great potential in imaging, diagnostics, and drug delivery.162 Keshtiara et al163 used Astragalus-Frankincense hydrogel (TFH) as the core and tannic acid (TA)-modified gold nanoparticles (AuNPs) self-assembled into a core-shell structure via hydrogen bonding, electrostatic interactions, and hydrophobic forces. Tannic acid modification imparts carrier stabilization, targeting, and antioxidant and anti-inflammatory functions through the chemical reactivity of its multiple hydroxyl groups. In a CIA rat model, intravenous administration (10 mg/kg) significantly reduced the arthritis index and serum pro-inflammatory factors (eg, IL-1β decreased by 61.01%), while liver and kidney function remained normal, highlighting the safety and immunomodulatory advantages of natural materials. Zheng et al38 used palladium nanoparticles (Pd NPs) as the photothermal core, through electrostatic adsorption of selenite ions (SeO2−) and reduction by ascorbic acid to form a selenium (Se) shell, followed by ester-bond coupling with hyaluronic acid (HA), to self-assemble the core-shell nanosystem Pd@Se-HA NPs. This system integrates the photothermal effect of Pd with the antioxidant and enzymatic activity of Se. Under near-infrared irradiation, the Pd core generates heat to ablate inflammatory cells, while the Se shell scavenges free radicals; together, they downregulate pro-inflammatory factors, achieving light-responsive, precise, on-demand therapy based on the “carrier-as-therapy” principle. Pentecost et al164 designed nano-diamonds modified with organic derivatives (ND-ODA) that were used to deliver dexamethasone (Dex). The carrier itself promotes the polarization of macrophages toward the M2 phenotype, synergizing with Dex to exert anti-inflammatory effects. In the CIA model, even low doses significantly improved the condition, whereas high doses actually exacerbated inflammation, demonstrating a dose-dependent effect. Xuetongsu (XTS), a cycloartane-type triterpenoid from Kadsura heteroclita, exerts dual anti-RA effects by suppressing the IL-23/IL-17/NF-κB axis in synovial cells and blocking RANKL/RANK/NFATc1-mediated osteoclastogenesis, with good oral bioavailability and low toxicity.165,166 Building on this pharmacological rationale, Deng et al167 encapsulated XTS into hollow mesoporous Prussian blue nanoparticles, which were subsequently coated with a hybrid membrane derived from red blood cells and osteoclasts, and further functionalized with folic acid–poly(ethylene glycol)–1,2‑distearoyl‑sn‑glycero‑3‑phosphoethanolamine, yielding the final formulation designated as FMPX nanoparticles. The system integrates ROS scavenging, photothermal activity, immune evasion (2.3-fold longer circulation), and dual targeting, effectively reducing paw swelling and bone erosion under NIR irradiation. MOF materials, on the other hand, exhibited greater structural programmability.168,169 Guo et al50 used TA (Tannic Acid) - Fe3⁺MOF as a core carrier for siRNA, which combines reactive oxygen species scavenging and gene silencing functions, resulting in a synergistic effect in regulating macrophage polarization. Chen et al170 developed 120-nm ruthenium nanoparticles forming a core–shell structure via coordination bonds. Photothermal therapy (PTT) combined with chemotherapy: 808 nm laser irradiation induces M2 polarization and triggers acid-responsive RES release (82% at pH 5.5), reducing the arthritis score from 4 to nearly 0 in CIA mice (Table 3). Table 3The Application of Self-Assembling Nanoparticles in Rheumatoid ArthritisTypeStructural UnitSelf-Assembly Driving ForceKey Physical and Chemical CharacterizationEffectiveness of Drug TherapyReferencesCLT/BRNPBilirubin-PEG conjugate (BRmPEG), Tripterygium wilfordii homofubicarpine (CLT)Hydrophobic interaction, π-π stackingSize: ~68.6 nm, PDI: 0.155, Zeta:-7.3 mV, EE: 72.6%, DL: 6.6%In Vivo Efficacy (AIA Rat Model): IV CLT 1 mg/kgJoint swelling↓ (~50%) + Arthritis score↓TNF-α↓, NO↓Cartilage erosion↓In Vitro Activity: Intracellular ROS↓LPS-induced NO↓[157]CDP-MPα-Methylprednisolone (MP), Cyclodextrin Polymer (CDP)Hydrophobic interaction, π-π stackingSize: 27 nm, PDI: 0.224, DL: 12.4%In Vivo Efficacy (CIA Mouse Model): Weekly IV 0.7/7 mg MP equivalent/kgArthritis score↓ (p < 0.006); Paw swelling→baselineSynovitis↓, Pannus↓, Bone erosion↓Superior to daily free MP; Reduced dosing frequency[158]PAT NPsTripterygin (TP), Poly-γ-glutamic acid, Di-tert-butyl aspartate hydrochloride (Asp)Hydrophobic interaction, π-πstacking, electrostatic interactionSize: 79 ± 18 nm, PDI: 0.18, Zeta: −32 mV, EE: 48.6%, DL: 19.2%In Vitro Activity: PAT NPs enhanced cytotoxicity vs free TP (24h IC50: 236±39.32 vs 47±12.34 nM)Significantly reduced apoptosis rate (7.2% vs 68.9%)Inhibited pro-inflammatory cytokine expressionIn Vivo Efficacy (TNF-α Transgenic Mice): Significantly improved survival rate (100% vs 70%)Alleviated joint inflammation, bone erosion, and cartilage lossNo significant hepatorenal toxicity (ALT, AST, CRE, BUN levels normal)[90]MTX@cNP-pp-PEG,MTX, PLGA-b-PDMA, matrix metalloproteinase-2 (MMP2), polyethylene glycol (PEG) chainHydrophobic interactions, π-π stackingSize: 74 nm (before MMP2 treatment) / 67 nm (after MMP2 treatment), Zeta: +13.7 mV (before MMP2 treatment) / +22.8 mV (after MMP2 treatment), EE: 93.7%, DL: 16.0%In Vitro Activity: Enhanced vs free MTX (24h IC50: 236±39.32 vs 47±12.34 nM)TNF-α↓, IL-6↓, IL-1β↓, iNOS↓[159]MTX-GC-SA NPsGlycol Chitosan-Stearic Acid (GC-SA), Methotrexate (MTX)Hydrophobic interactionSize: 235.8 ± 2.67 nm, PDI: 0.149 ± 0.017, Zeta: −20.4 ± 1.13 mV, EE:73.4 ± 3.7%In Vitro Activity: IC50: 9.40 μg/mL ↓ (vs free MTX: 15.46 μg/mL)In Vivo Efficacy (CIA Model): Arthritis score↓, Paw thickness↓Pro-inflammatory cytokines (IL-1β, TNF-α) ↓[160]LEF-HA-proposomesPropylene glycol (PG), Soya phosphatidylcholine (SPC), Chitosan (CS), Hyaluronic acid (HA), Leflunomide (LEF)Hydrophobic interactionSize: 178.7 ± 1.8 nm (bare LEF-proposomes) / 269.47 ± 6.7 nm (CS-coated) / 342.62 ± 8.3 nm (HA-coated), PDI: 0.174, Zeta: −54.9 ± 5.16 mV (bare) / +38.4 ± 4.2 mV (CS-coated) / −50.46 ± 6.4 mV (HA-coated), EE:94.12 ± 1.7%In Vivo Efficacy (CIA Model): Arthritis score ↓Paw thickness ↓Synovitis ↓, Cartilage erosion ↓, Bone destruction ↓[161]TA/AuNPsXihuangshiGum-Frankincense Gum Hydrogel Core (TFH), Tannic Acid (TA), AuNPsHydrogen bonding, electrostatic interactions, and hydrophobic interactionsSize: ~35 ± 9 nm (TFH) / ~168 ± 46 nm (TFH@TA) / ~225 ± 75 nm (TFH@TA/AuNPs), EE: 60% (10-HAD), DL: 7.3% (10-HDA)In Vivo Efficacy (CIA Model): Arthritis index↓, Paw thickness↓IL-1β↓61.01%, TNF-α↓26.06%, IL-6↓34.89%; IL-10↑87.80%Tissue damage↓Safety: Hepatorenal function: Normal[163]Pd@Se-HA NPsPalladium nanoparticles, selenium nanoparticles, Hyaluronic acid (HA)Electrostatic interactions, hydrogen bondsSize: ~5 ± 2 nm (Pd NPs) / ~125 nm (Pd@Se-HA NPs)In Vivo Efficacy: Arthritis score↓ (from 4 to near-normal)TNF-α↓, IL-1β↓, IL-6↓Joint inflammation↓ and Cartilage erosion↓[38]ND-ODA-DexOctadecylamine-functionalized nanodiamond (ND-ODA), Dexamethasone (Dex)Hydrophobic interaction, Electrostatic interactionSize: ~5.1 ± 2.2 nm (primary ND-ODA), Zeta: −11.9 mV (ND-ODA) / −23.8 mV (ND-ODA-Dex), DL: ~10 mg Dex / g ND-ODAIn Vivo Efficacy (CIA Model): Arthritis score↓ (P < 0.01)Bone volume→Inflammatory cell infiltration↓, F4/80↓, iNOS↓, TNF-α↓[164]FMPX NPsPrussian blue (PB) hollow mesoporous NPs, Xuetongsu (XTS), Hybrid membrane (ROM): RBCm + OCm, DSPE-PEG2000-FAMetal coordination, Hydrophobic interactionSize ≈170 nm (FMPX), PDI 0.23, Zeta ≈ −6 mV (FA+), EE% ≈80%, DL ≈19.7%In Vitro: Macrophage viability ↓ (35.66%)Osteoclast viability ↓ (26.58%)G0/G1 phase ↑, ROS ↓p-NF-κB ↓, IκB-α ↑IL-6, TNF-α, IL-1β, MMP9 ↓RANKL, RANK, NFATc1, TRAP ↓In Vivo (AIA Rat): Paw swelling ↓ (12.10 → 8.24 mm); Arthritis score ↓Synovial hyperplasia, cartilage erosion, bone erosion ↓IL-6, TNF-α, IL-1β, MMP9 in joint ↓p-NF-κB, RANKL, RANK, NFATc1, TRAP ↓; IκB-α ↑Plasma half-life ↑ (2.32×)Toxicity: None observed[167]TFSB, siRNATannic acid (TA), Fe3⁺, Bovine Serum albumin (BSA), siRNAMetal coordinationSize: 144 nm (TFS) / 166 nm (TFSB), Zeta: −22.6 mV (TFS) / −17.7 mV (TFSB), EE: 71.3%, DL: 5.3%In Vivo Efficacy (CIA Model): Arthritis score↓ (from ~12 to 4, p < 0.01); Paw thickness↓ (~40%)TNF-α↓ >50%, IL-6↓ >50%Safety: Hematological parameters: Normal[50]QRu-PLGA-RES-DS NPsResveratrol (RES), Quadrilateral ruthenium nanoparticles (QRu NPs), PLGA, Dextran sulfate (DS)Metal coordinationSize: ~120 nm (QRu NPs) / ~150–200 nm (PLGA vesicles) / 150 ± 30 nm (QRu-PLGA-RES-DS NPs, DLS), EE: 10.2%In Vivo Efficacy (CIA Model): Arthritis score↓ (from 4 to near 0)TNF-α↓ (259.11 pg/mL); IL-1β↓ ~50%, IL-6↓ ~50%; IL-10↑ (35.67 pg/mL)Cartilage protection↑[170]Abbreviations: NPs, nanoparticles; PDI, polydispersity index; EE, encapsulation efficiency; DL, drug loading; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; TNF-α, tumor necrosis factor-alpha; IL, interleukin; IC50, half-maximal inhibitory concentration; NO, nitric oxide; ROS, reactive oxygen species; LPS, lipopolysaccharide; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRE, creatinine; BUN, blood urea nitrogen; MMP2, matrix metalloproteinase-2; PEG, polyethylene glycol; PLGA, poly(lactic-co-glycolic acid); iNOS, inducible nitric oxide synthase; AuNPs, gold nanoparticles; NF-κB, nuclear factor kappa B; RANKL, receptor activator of nuclear factor κB ligand; NFATc1, nuclear factor of activated T cells cytoplasmic 1; TRAP, tartrate-resistant acid phosphatase; siRNA, small interfering RNA; DLS, dynamic light scattering; FA, folic acid; ↑, increase; ↓, decrease; →, direction of action/process; >, greater than; <, less than. The Application of Self-Assembling Nanoparticles in Rheumatoid Arthritis IV CLT 1 mg/kg IV CLT 1 mg/kg Joint swelling↓ (~50%) + Arthritis score↓ Joint swelling↓ (~50%) + Arthritis score↓ TNF-α↓, NO↓ TNF-α↓, NO↓ Cartilage erosion↓ Cartilage erosion↓ Intracellular ROS↓ Intracellular ROS↓ Weekly IV 0.7/7 mg MP equivalent/kg Weekly IV 0.7/7 mg MP equivalent/kg Arthritis score↓ (p < 0.006); Paw swelling→baseline Arthritis score↓ (p < 0.006); Paw swelling→baseline Synovitis↓, Pannus↓, Bone erosion↓ Synovitis↓, Pannus↓, Bone erosion↓ PAT NPs enhanced cytotoxicity vs free TP (24h IC50: 236±39.32 vs 47±12.34 nM) PAT NPs enhanced cytotoxicity vs free TP (24h IC50: 236±39.32 vs 47±12.34 nM) Significantly reduced apoptosis rate (7.2% vs 68.9%) Significantly reduced apoptosis rate (7.2% vs 68.9%) Inhibited pro-inflammatory cytokine expression Inhibited pro-inflammatory cytokine expression Significantly improved survival rate (100% vs 70%) Significantly improved survival rate (100% vs 70%) Alleviated joint inflammation, bone erosion, and cartilage loss Alleviated joint inflammation, bone erosion, and cartilage loss Enhanced vs free MTX (24h IC50: 236±39.32 vs 47±12.34 nM) Enhanced vs free MTX (24h IC50: 236±39.32 vs 47±12.34 nM) IC50: 9.40 μg/mL ↓ (vs free MTX: 15.46 μg/mL) IC50: 9.40 μg/mL ↓ (vs free MTX: 15.46 μg/mL) Arthritis score↓, Paw thickness↓ Arthritis score↓, Paw thickness↓ Arthritis score ↓ Arthritis score ↓ Paw thickness ↓ Paw thickness ↓ Synovitis ↓, Cartilage erosion ↓, Bone destruction ↓ Synovitis ↓, Cartilage erosion ↓, Bone destruction ↓ Arthritis index↓, Paw thickness↓ Arthritis index↓, Paw thickness↓ IL-1β↓61.01%, TNF-α↓26.06%, IL-6↓34.89%; IL-10↑87.80% IL-1β↓61.01%, TNF-α↓26.06%, IL-6↓34.89%; IL-10↑87.80% Tissue damage↓ Tissue damage↓ Arthritis score↓ (from 4 to near-normal) Arthritis score↓ (from 4 to near-normal) TNF-α↓, IL-1β↓, IL-6↓ TNF-α↓, IL-1β↓, IL-6↓ Arthritis score↓ (P < 0.01) Arthritis score↓ (P < 0.01) Bone volume→ Bone volume→ Inflammatory cell infiltration↓, F4/80↓, iNOS↓, TNF-α↓ Inflammatory cell infiltration↓, F4/80↓, iNOS↓, TNF-α↓ Macrophage viability ↓ (35.66%) Macrophage viability ↓ (35.66%) Osteoclast viability ↓ (26.58%) Osteoclast viability ↓ (26.58%) G0/G1 phase ↑, ROS ↓ G0/G1 phase ↑, ROS ↓ p-NF-κB ↓, IκB-α ↑ p-NF-κB ↓, IκB-α ↑ IL-6, TNF-α, IL-1β, MMP9 ↓ IL-6, TNF-α, IL-1β, MMP9 ↓ RANKL, RANK, NFATc1, TRAP ↓ RANKL, RANK, NFATc1, TRAP ↓ Paw swelling ↓ (12.10 → 8.24 mm); Arthritis score ↓ Paw swelling ↓ (12.10 → 8.24 mm); Arthritis score ↓ Synovial hyperplasia, cartilage erosion, bone erosion ↓ Synovial hyperplasia, cartilage erosion, bone erosion ↓ IL-6, TNF-α, IL-1β, MMP9 in joint ↓ IL-6, TNF-α, IL-1β, MMP9 in joint ↓ p-NF-κB, RANKL, RANK, NFATc1, TRAP ↓; IκB-α ↑ p-NF-κB, RANKL, RANK, NFATc1, TRAP ↓; IκB-α ↑ Plasma half-life ↑ (2.32×) Plasma half-life ↑ (2.32×) Toxicity: None observed Toxicity: None observed Arthritis score↓ (from ~12 to 4, p < 0.01); Paw thickness↓ (~40%) Arthritis score↓ (from ~12 to 4, p < 0.01); Paw thickness↓ (~40%) TNF-α↓ >50%, IL-6↓ >50% TNF-α↓ >50%, IL-6↓ >50% Arthritis score↓ (from 4 to near 0) Arthritis score↓ (from 4 to near 0) TNF-α↓ (259.11 pg/mL); IL-1β↓ ~50%, IL-6↓ ~50%; IL-10↑ (35.67 pg/mL) TNF-α↓ (259.11 pg/mL); IL-1β↓ ~50%, IL-6↓ ~50%; IL-10↑ (35.67 pg/mL) Abbreviations: NPs, nanoparticles; PDI, polydispersity index; EE, encapsulation efficiency; DL, drug loading; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; TNF-α, tumor necrosis factor-alpha; IL, interleukin; IC50, half-maximal inhibitory concentration; NO, nitric oxide; ROS, reactive oxygen species; LPS, lipopolysaccharide; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRE, creatinine; BUN, blood urea nitrogen; MMP2, matrix metalloproteinase-2; PEG, polyethylene glycol; PLGA, poly(lactic-co-glycolic acid); iNOS, inducible nitric oxide synthase; AuNPs, gold nanoparticles; NF-κB, nuclear factor kappa B; RANKL, receptor activator of nuclear factor κB ligand; NFATc1, nuclear factor of activated T cells cytoplasmic 1; TRAP, tartrate-resistant acid phosphatase; siRNA, small interfering RNA; DLS, dynamic light scattering; FA, folic acid; ↑, increase; ↓, decrease; →, direction of action/process; >, greater than; <, less than. Self-Assembling Hydrogels Wu et al171 used an IκB kinase inhibitor peptide (IOK peptide) as a carrier; a hydrogel was formed via self-assembly through hydrophobic interactions, hydrogen bonding, and π-π stacking, loaded with bismuth nanosheets and methotrexate (MTX encapsulation rate: 96.91%). Under the acidic microenvironment (pH 5.8) of RA lesions, changes in the peptide scaffold conformation increase the MTX release rate by approximately 2.6-fold, enabling acid-responsive targeted release; near-infrared laser irradiation activates the photothermal and photodynamic effects of the bismuth nanosheets, synergistically enhancing anti-inflammatory and immunomodulatory effects (Figure 7). In vivo treatment efficacy of BiPM@IOK hydrogel. A Representative infrared thermal images of right hind ankle joints of AIA rats with different treatments under NIR (808 nm, 1 W/cm2) irradiation for 5 min. (B) Temperature increase curves according to (A). Representative images of right hind paws (C) and paws swelling degree (D) of normal and AIA rats with different treatments, ***p < 0.001. Concentration of TNF-α (E) and IL-1β (F) of synovium tissue samples detected by ELISA kit, ***, p < 0.001. (G) Safranin O staining of joints after various administrations. Reprinted from ref171 with permission. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). Notes: The original figure was reproduced from Ref,171 where the two subpanels were both labeled as (F). For clarity in our manuscript, we have relabeled the lower panel as (G). Wang et al172 constructed a nano-system based on poly-γ-glutamic acid-grafted di-tert-butyl L-aspartate hydrochloride (PA) loaded with indocyanine green (ICG) as a Tg mice, PAT-ICG exhibited significantly higher fluorescence in inflamed joints than controls at 24 h, with joint retention up to 80 h; meanwhile, PAT treatment markedly reduced paw thickness, improved joint clinical scores, and prolonged balance beam times, confirming its dual function of targeted imaging and anti-arthritic efficacy. Kumar et al173 developed an MMP-9-responsive injectable hydrogel based on GMS to deliver budesonide (Bud) via CD44 targeting. MMP-9 at 1.5 and 5 μg/mL increased Bud release by 20% and 15%, respectively, demonstrating concentration-dependent release. Wang et al174 grafted HA with hydrophobic PCT segments to form HA-PCT, co-assembling with Cel-loaded PECT nanoparticles into an injectable, self-healing hydrogel. HA provides CD44-targeted delivery, while Cel inhibits TLR4/NF-κB, reducing M1 macrophage proportion from 18.3% to 5.01%. Kim et al175 constructed azide-modified hyaluronic acid/dopamine-modified chitosan/azide-capped poly(lactic-co-glycolic acid)-poly(ethylene glycol) block copolymer hydrogel(HA-N3/DA-NOCCL/PLA-b-PEG-N3). This hydrogel achieves dual-functional synergy via an NO-cleavable crosslinker: it both scavenges pathogenic NO and utilizes NO concentration to trigger the sequential release of dexamethasone (Dexa), resulting in a 60% reduction in joint NO levels in the CIA model. Cheng et al,176 by encapsulating cGAS (cyclic GMP-AMP synthase) inhibitor RU521 as cationic nanoparticles within a PEG hydrogel to form the NiH composite system. Via a “clearance–inhibition” dual mechanism, extracellular cfDNA is cleared, and the cGAS/IFN-β axis is blocked. IVIS imaging confirmed prolonged drug retention in draining lymph nodes with reduced systemic dissemination. (Figure 8) Qindeel et al177 designed MTX-loaded nanomicelles that were incorporated into a hydrogel and combined with eucalyptus oil as a penetration enhancer to form a stable drug delivery system. This system can target inflamed joints via the ELVIS effect and is efficiently taken up by activated macrophages, while the hydrogel matrix delays drug release and enhances local retention. Pharmacokinetic data show that its AUC, half-life, and mean residence time are significantly improved compared to free MTX (Table 4). NiH prolonged drug retention in LNs while reducing systemic drug dissemination. (A) Gelation of blank hydrogel and NiH as shown by vial tilting. (B) Relative mouse body weights after s.c. injection of cNPs-H and PBS control (cNPs: 40 mg kg−1). (C) Flow cytometry results showing mouse PBMC immune cell counts 6 days after s.c. injection of cNPs-H and PBS control. (D) In vitro release kinetics of RU from NiH (n = 3). (E) IVIS images of C57BL/6 mice over 1–5 days after s.c. injection of DIR/cNPs-H and controls (n = 4). (F) Quantification of DIR fluorescence intensities in the draining inguinal LNs of the above mice. (G) The percentage of total fluorescence in LNs relative to that in abdomen from the above mice. (H) IVIS images of ex vivo LNs from the above mice 5 days after administration. (I and J) Flow cytometric analysis of DIR uptake by LN-residing macrophages and DCs. Data: mean ± SD (D) and mean ± s.e.m. p-values were determined by one-way (G and J) or two-way (B, C, F, I) ANOVA, followed by Tukey’s multiple comparison test (ns: not significant; *p < 0.05; **p < 0.01; ***p < 0.001). Reprinted from ref176 with permission. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). Table 4The Application of Self-Assembling Hydrogels in Rheumatoid ArthritisTypeStructural UnitSelf-Assembly Driving ForceEffectiveness of Drug TherapyReferencespH-Sensitive Peptide Hydrogel ((BiPM@IOK))Bismuth Nanoplatelets (BiNS/PEI, PEI-modified), Methotrexate (MTX)Hydrophobic interactions, hydrogen bonding, π-π stackingIn vivo Efficacy (AIA Model): Fibroblast-like synoviocyte (FLS) viability↓ (to 18.9%)Paw thickness ratio↓ (from 1.68 to 1.15)[171]TGMS HydrogelTriglyceride monostearate (TGMS), psoralen, calcium peroxideHydrophobic interaction, hydrogen bondingIn vivo Efficacy (CIA Model): Paw thickness↓, Arthritis clinical score↓, Serum pro-inflammatory cytokines (IL-6, TNF-α)↓Bone erosion↓Joint inflammation↓Safety: Liver and kidney function indices: Normal[172]ER hydrogelGlyceryl Monostearate (GMS), Budesonide (Bud)Hydrophobic interactionIn vivo Efficacy (CIA Model): Paw thickness↓ (50%, p < 0.01)Pro-inflammatory cytokines (TNF-α, IL-1β)↓ (p < 0.05)MPO↓, NO↓, CRP↓ (p < 0.001)Cartilage score↑; COX-2↓, iNOS↓[173]HP@CEL HydrogelHyaluronic acid (HA), PCT (polycaprolactone-co-1,4,8-trioxaspirodecane) Celastrol (CEL)Hydrophobic interactions, hydrogen bonding,π-π stackingIn vivo Efficacy (CIA Model): Ankle diameter↓, Paw thickness↓, Clinical score↓Bone mineral density (BMD)↑Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) mRNA expression↓Safety: No obvious toxicity in major organs (H&E staining confirmed)[174]M-NO HydrogelAzide-functionalized hyaluronic acid (HA-N3) Nitric oxide (NO) PLA-b-PEG-N3 polymer aggregates Dexamethasone (Dexa)Hydrophobic interactionIn vivo Efficacy (CIA Model): Alleviates arthritis symptoms and improves motor activity.Bone erosion and joint damage↓Pro-inflammatory cytokines and NO levels↓[175]NiHCationic nanoparticles (cNPs), amphiphilic star-shaped polymer PEG-PDMA-PDPA (PGAA)Hydrophobic interactions, hydrogen bonding, π-π stackingIn vivo Efficacy (CIA Model): Clinical score↓, Paw thickness↓cfDNA↓ (32%)Spleen regulatory T cells (Treg) proportion↑ (42%)Pro-inflammatory cytokines (TNF-α, IL-6)↓ (p < 0.001)[176]MTX-NMs-based hydrogelMethotrexate (MTX), Polycaprolactone-Polyethylene Glycol-Polycaprolactone (PCL-PEG-PCL), Carbopol 934-based hydrogel, Eucalyptus oil (EO)Hydrophobic interactionIn vivo Efficacy (CIA Model): Clinical score↓, Paw thickness↓Pro-inflammatory cytokines (TNF-α, IL-12)↓Pharmacokinetics: AUC: 3.68-fold increase vs oral free MTXHalf-life: 4.34-fold extension vs oral free MTXSafety: Mild hepatotoxicity (ALT/AST levels normal)[177]Abbreviations: NPs, nanoparticles; AUC, area under the curve; COX-2, cyclooxygenase-2; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; MTX, methotrexate; FLS, fibroblast-like synoviocyte; TNF-α, tumor necrosis factor-alpha; IL, interleukin; BMD, bone mineral density; cfDNA, cell-free DNA; Treg, regulatory T cell; MPO, myeloperoxidase; CRP, C-reactive protein; NO, nitric oxide; iNOS, inducible nitric oxide synthase; PEG, polyethylene glycol; PLA, polylactic acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ↑, increase; ↓, decrease; →, direction of action/process; >, greater than; <, less than. The Application of Self-Assembling Hydrogels in Rheumatoid Arthritis Fibroblast-like synoviocyte (FLS) viability↓ (to 18.9%) Fibroblast-like synoviocyte (FLS) viability↓ (to 18.9%) Paw thickness↓, Arthritis clinical score↓, Serum pro-inflammatory cytokines (IL-6, TNF-α)↓ Paw thickness↓, Arthritis clinical score↓, Serum pro-inflammatory cytokines (IL-6, TNF-α)↓ Bone erosion↓ Bone erosion↓ Joint inflammation↓ Joint inflammation↓ Paw thickness↓ (50%, p < 0.01) Paw thickness↓ (50%, p < 0.01) Pro-inflammatory cytokines (TNF-α, IL-1β)↓ (p < 0.05) Pro-inflammatory cytokines (TNF-α, IL-1β)↓ (p < 0.05) MPO↓, NO↓, CRP↓ (p < 0.001) MPO↓, NO↓, CRP↓ (p < 0.001) Ankle diameter↓, Paw thickness↓, Clinical score↓ Ankle diameter↓, Paw thickness↓, Clinical score↓ Bone mineral density (BMD)↑ Bone mineral density (BMD)↑ Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) mRNA expression↓ Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) mRNA expression↓ Alleviates arthritis symptoms and improves motor activity. Alleviates arthritis symptoms and improves motor activity. Bone erosion and joint damage↓ Bone erosion and joint damage↓ Pro-inflammatory cytokines and NO levels↓ Pro-inflammatory cytokines and NO levels↓ Clinical score↓, Paw thickness↓ Clinical score↓, Paw thickness↓ cfDNA↓ (32%) cfDNA↓ (32%) Spleen regulatory T cells (Treg) proportion↑ (42%) Spleen regulatory T cells (Treg) proportion↑ (42%) Clinical score↓, Paw thickness↓ Clinical score↓, Paw thickness↓ Pro-inflammatory cytokines (TNF-α, IL-12)↓ Pro-inflammatory cytokines (TNF-α, IL-12)↓ AUC: 3.68-fold increase vs oral free MTX AUC: 3.68-fold increase vs oral free MTX Half-life: 4.34-fold extension vs oral free MTX Half-life: 4.34-fold extension vs oral free MTX Abbreviations: NPs, nanoparticles; AUC, area under the curve; COX-2, cyclooxygenase-2; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; MTX, methotrexate; FLS, fibroblast-like synoviocyte; TNF-α, tumor necrosis factor-alpha; IL, interleukin; BMD, bone mineral density; cfDNA, cell-free DNA; Treg, regulatory T cell; MPO, myeloperoxidase; CRP, C-reactive protein; NO, nitric oxide; iNOS, inducible nitric oxide synthase; PEG, polyethylene glycol; PLA, polylactic acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ↑, increase; ↓, decrease; →, direction of action/process; >, greater than; <, less than. Self-Assembled Micelles Han et al178 constructed a dextran sulfate-cis-aconitic anhydride-dexamethasone (DS-cad-DXM) copolymer micelle. DS promotes scavenger receptor-mediated macrophage uptake, while DXM suppresses NF-κB-driven inflammation. Guo et al179 developed Achyranthes bidentata polysaccharide/dextran sulfate (Abps/DS) dual-responsive micelles (D&A@Cel) loaded with celastrol (Cel) and curcumin (Cur). MMP-2 cleavage (PVGLIG peptide) and ROS-responsive thioketone bond breakage ensure drug release only at the inflammation site. Zhou et al180 constructed an HA-based multifunctional micelle that combines the antioxidant activity of CeO2 nanoenzymes with the anti-inflammatory effects of rhein, synergistically promoting M2 polarization of macrophages. Fan et al181 used hyaluronic acid (HA) as a hydrophilic backbone and covalently linked the hydrophobic drug curcumin (Cur) via ester bonds, forming HA-Cur nanomicelles. Cur degradation was reduced from 80% to 20%, and the joint friction coefficient dropped from 0.085 to 0.027, achieving synergistic anti-inflammatory and lubricating therapy. Batra et al182 constructed supramolecular polymeric micelles using β-cyclodextrin (β-CD) to load the hydrophobic drug dioscidin (with a drug loading capacity of 92.45%). Targeted delivery was achieved by conjugating the micelles with an anti-CD64 antibody. The drug downregulates the expression of pro-inflammatory factors such as TNF-α and IL-15 by inhibiting the NF-κB pathway. Zhang et al183 designed amphiphilic copolymers (PNIPAAm/EAB-PPPs) with poly(N-isopropylacrylamide) (PNIPAAm) and ethyl 4-aminobenzoate (EAB) as side chains that self-assemble via hydrophobic interactions to load indomethacin (IND). The system passively targets inflamed joints via EPR, with a biphasic release profile: 95% burst release within 5 h, followed by sustained release over 5 days, avoiding systemic gastrointestinal side effects. Li et al184 developed a new drug delivery system of pH sensitive polymeric micelles based on an acid-labile hydrazone bond. Amphiphilic conjugates of a PEG-based derivative and the hydrophobic drug prednisolone (PD) self-assembled into PD micelles with a drug loading of 19.29%. At pH 5.5, nearly 100% of PD is released within 96 h. In CIA mice, AUC and Cmax were 4.63- and 2.50-fold higher than free PD. Hao et al185 used methotrexate (MTX)-conjugated polymer (MTX-PEI-LA) and monomethoxy polyethylene glycol-polylactic acid (mPEG-LA) as building blocks, which self-assemble via hydrophobic interactions to form MTX-conjugated polymer mixed micelles (M PHMs) loaded with microRNA-124 (miR-124), to construct an M PHMs/miR-124 drug delivery system. M-PHMs/miR-124 combines MTX-mediated anti-inflammation and miR-124-induced anti-bone-resorption, significantly reducing joint swelling and bone erosion in AIA rats with superior efficacy over controls (Figure 9) (Table 5). Therapeutic efficacy of M-PHMs/miR-124 in vivo. Left ankle thickness (A) and clinical score of AIA rats (B) treated with various drug formulations were obtained (*P <0.05, **P <0.01, ***P <0.001, PHMs/miR-124, PHMs/miR-124 NC, and MTX separately compared with M-PHMs/miR-124). (C) Photographs of hind paws and representative X-ray of the left ankle (D) from AIA rats treated with various drug formulations. Rats without AIA were set as normal group. Values are mean ±SEM (n=6). Reprinted from ref185 with permission. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). Table 5Applications of Self-Assembled Micelles in Rheumatoid ArthritisTypeStructural UnitSelf-Assembly Driving ForceEffectiveness of Drug TherapyReferencesDXM@DS-cad-DXMDextran sulfate (DS) Cycloartane acid anhydride (CAD) Dexamethasone (DXM) Dextran (DEX)Hydrophobic interactionIn vivo Efficacy (AIA Rat Model): Pro-inflammatory cytokines (IL-1β, IL-6)↓ (p < 0.05)Bone structure↑Accumulation↑ (2.8-fold vs control)[178]Dual-Response Nanodelivery System D&A@CelDS-PVGLIG-Cel (Dextran sulfate-PVGLIG-Tripterygium wilfordii homofubic acid) Abps-tk-Cur (Achyranthes bidentata polysaccharide-Thioxanthone-Curcumin)Hydrophobic interactionIn vivo Efficacy (AIA Rat Model): Joint swelling rate↓ (50%, p < 0.05); Arthritis clinical score↓ (from 3.5 to 1.2)Synovial hyperplasia↓ + Bone erosion↓[179]HA@RH-CeO2Hyaluronic acid (HA), β-cyclodextrin (CD), adamantane-d-rhein (AD-TK-RH), cerium dioxide nanoenzyme (CeO2)Hydrophobic interactionIn vivo Efficacy (CIA Rat Model): Inflamed joint temperature↓ (from 33.1°C to 27.5°C)Pro-inflammatory cytokines (TNF-α, IL-6)↓ (p < 0.01)Cartilage proteoglycan content↑ (safranin O staining)Bone erosion↓[180]HA/CurmicelleHyaluronic Acid (HA) Curcumin (Cur)Hydrophobic interactionIn vivo Efficacy (CFA Rat Model): Paw edema↓ (~30%, p < 0.05)Pro-inflammatory cytokines (TNF-α, IL-1)↓, VEGF↓Smoother cartilage surface + Reduced[181]Supramolecular polymer micellesβ-cyclodextrin (β-CD), carboxymethyl cellulose (CMC), urea, diosgenin, anti-CD64 antibodyHydrophobic interactionIn vivo Efficacy (CIA Rat Model): Paw diameter↓ (from 6.47 mm to 4.59 mm)Pro-inflammatory cytokines↓ (TNF-α: 10.81 pg/mL; IL-15: 6.88 pg/mL)[182]PNIPAAm/EAB-PPPs, Indomethacin MicellesPNIPAAm/EAB-PPPs, Indomethacin MicellesHydrophobic interactions, hydrogen bonding,π-π stackingIn vivo Efficacy (Carrageenan-Induced Acute Model): IV micelles (4.5 mg IND equivalent/kg)Paw swelling volume↓ (from 0.60 ± 0.05 mL to 0.29 ± 0.10 mL, 3–7 h post-administration; p < 0.01)In vivo Efficacy (Complete Freund’s Adjuvant (CFA) Model): IV micelles (1.5 mg IND equivalent/kg)Paw edema intensity↓ (from 0.78 ± 0.06 mL to 0.34 ± 0.04 mL, day 15; p < 0.05); Normal weight gain[183]pH-sensitive polymeric micellePrednisolone (PD) PEG-Derivative (APN)Hydrophobic interactionPharmacokinetics: AUC: 4.63-fold increase vs free PDCmax: 2.50-fold increase vs free PDIn Vivo Efficacy (CIA Rat Model): Paw thickness↓, Arthritis score↓ (p < 0.05)Pro-inflammatory cytokines↓ (p < 0.05)[184]M-PHMsMethotrexate-conjugated polymer (MTX-PEI-LA), mPEG-LA, microRNA-124Electrostatic interactionIn vivo Efficacy (AIA Rat Model): Paw thickness↓ (p < 0.001), Clinical score↓, Serum pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)↓ (p < 0.05)TRAP-positive osteoclasts↓ (5.12-fold decrease)Cartilage integrity↑[185]Abbreviations: AUC, area under the curve; Cmax, maximal plasma concentration; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; CFA, complete Freund’s adjuvant; TNF-α, tumor necrosis factor-alpha; IL, interleukin; VEGF, vascular endothelial growth factor; TRAP, tartrate-resistant acid phosphatase; MTX, methotrexate; PEG, polyethylene glycol; β-CD, β-cyclodextrin; CMC, carboxymethyl cellulose; IND, indomethacin; ↑, increase; ↓, decrease; →, direction of action/process; >, greater than; <, less than. Applications of Self-Assembled Micelles in Rheumatoid Arthritis Pro-inflammatory cytokines (IL-1β, IL-6)↓ (p < 0.05) Pro-inflammatory cytokines (IL-1β, IL-6)↓ (p < 0.05) Bone structure↑ Bone structure↑ Joint swelling rate↓ (50%, p < 0.05); Arthritis clinical score↓ (from 3.5 to 1.2) Joint swelling rate↓ (50%, p < 0.05); Arthritis clinical score↓ (from 3.5 to 1.2) Inflamed joint temperature↓ (from 33.1°C to 27.5°C) Inflamed joint temperature↓ (from 33.1°C to 27.5°C) Pro-inflammatory cytokines (TNF-α, IL-6)↓ (p < 0.01) Pro-inflammatory cytokines (TNF-α, IL-6)↓ (p < 0.01) Cartilage proteoglycan content↑ (safranin O staining) Cartilage proteoglycan content↑ (safranin O staining) Paw edema↓ (~30%, p < 0.05) Paw edema↓ (~30%, p < 0.05) Pro-inflammatory cytokines (TNF-α, IL-1)↓, VEGF↓ Pro-inflammatory cytokines (TNF-α, IL-1)↓, VEGF↓ Paw diameter↓ (from 6.47 mm to 4.59 mm) Paw diameter↓ (from 6.47 mm to 4.59 mm) IV micelles (4.5 mg IND equivalent/kg) IV micelles (4.5 mg IND equivalent/kg) Paw swelling volume↓ (from 0.60 ± 0.05 mL to 0.29 ± 0.10 mL, 3–7 h post-administration; p < 0.01) Paw swelling volume↓ (from 0.60 ± 0.05 mL to 0.29 ± 0.10 mL, 3–7 h post-administration; p < 0.01) IV micelles (1.5 mg IND equivalent/kg) IV micelles (1.5 mg IND equivalent/kg) AUC: 4.63-fold increase vs free PD AUC: 4.63-fold increase vs free PD Cmax: 2.50-fold increase vs free PD Cmax: 2.50-fold increase vs free PD Paw thickness↓, Arthritis score↓ (p < 0.05) Paw thickness↓, Arthritis score↓ (p < 0.05) Paw thickness↓ (p < 0.001), Clinical score↓, Serum pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)↓ (p < 0.05) Paw thickness↓ (p < 0.001), Clinical score↓, Serum pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)↓ (p < 0.05) TRAP-positive osteoclasts↓ (5.12-fold decrease) TRAP-positive osteoclasts↓ (5.12-fold decrease) Abbreviations: AUC, area under the curve; Cmax, maximal plasma concentration; CIA, collagen-induced arthritis; AIA, adjuvant-induced arthritis; CFA, complete Freund’s adjuvant; TNF-α, tumor necrosis factor-alpha; IL, interleukin; VEGF, vascular endothelial growth factor; TRAP, tartrate-resistant acid phosphatase; MTX, methotrexate; PEG, polyethylene glycol; β-CD, β-cyclodextrin; CMC, carboxymethyl cellulose; IND, indomethacin; ↑, increase; ↓, decrease; →, direction of action/process; >, greater than; <, less than. Self-Assembling Microneedles Lu et al186 developed a soluble microneedle patch composed of hyaluronic acid (HA) and chondroitin sulfate (CS) to co-deliver loxoprofen (Lox) and tofacitinib (Tof). Lox, as a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX)to reduce prostaglandin synthesis and alleviate pain; Tof, as a JAK inhibitor, blocks the JAK-STAT pathway and downregulates pro-inflammatory cytokines. The microneedles integrate photothermal therapy (PTT) mediated by gold nanoparticles. Irradiation with an 808 nm near-infrared laser not only produces an anti-inflammatory thermal effect but also triggers drug release through localized heat generation, thereby enhancing intra-articular drug penetration and uptake by target cells. In a carrageenan-induced rat model, this “light-heat-drug” triple therapy reduced joint swelling from 34.8% to 3.1% and effectively downregulated the expression of key genes in the JAK-STAT pathway. Liu et al187 used methoxy polyethylene glycol-polylactic acid (mPEG-PLA) diblock copolymers and hyaluronic acid (HA) as building blocks. We self-assembled nanomicelles loaded with methotrexate (MTX) via hydrophobic interactions and integrated them into soluble microneedles to construct an MTX nanomicelle-based soluble microneedle drug delivery system. This system combines the advantages of painless transdermal delivery via microneedles with the active targeting of CD44 receptors by hyaluronic acid. Under in vitro conditions at pH 5.0, it achieves a release rate of 80% within 30 minutes, enabling rapid drug delivery. Lin et al188 developed indomethacin (IND) -loaded PLGA nanoparticles that were self-assembled with neutrophil membranes (NeuM) to form drug-loaded nanoparticles, which were then incorporated into a biodegradable biopolymer microneedle patch. The neutrophil membrane coating prolongs circulation time and, through its surface receptors, actively targets and adheres to the endothelium of inflamed blood vessels, while simultaneously neutralizing pro-inflammatory factors such as TNF-α and IL-1β, thereby achieving a synergistic “drug delivery–immune regulation” effect. In the CIA model, this system effectively controlled the disease score to ≤3 points. Hua et al189 designed a dissolvable microneedle patch (TPH/CH MN) co-loading two human serum albumin (HSA)-coated nanocomplexes: thioketal-crosslinked fluorinated polyethyleneimine 1.8K/pPUMA@HSA (TPH) and celastrol@HSA (CH). TPH nanocomplexes induce apoptosis of rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) via upregulation of the pro-apoptotic gene PUMA, while CH nanocomplexes inhibit the NF-κB pathway in macrophages and promote M2 polarization. In CIA mice, this patch markedly alleviated hind paw swelling, reduced paw thickness and clinical scores, showed no significant body weight changes, and micro-CT confirmed effective protection against bone erosion and joint destruction, collectively demonstrating synergistic inhibition of synovial hyperplasia and bone/cartilage erosion. (Figure 10). Inhibitory effect of TPH/CH MN on arthritic progression in CIA mice. (A) Schematic illustration of the treatment for CIA mice by TPH/CH MN. (B) Representative hind paw images in normal, saline, TPH/CH NCs, TPH MN, CH MN and TPH/CH MN groups at day 30 and day 48. (C) Body weight change vs time in different groups. (D) Paw thickness of mice in normal, saline, TPH/CH NCs, TPH MN, CH MN and TPH/CH MN groups. (E) Clinical scores of mice at the end of the therapy. (F) Micro-CT analysis of the hind paw of mice after treatments. Data are shown as the mean ±SD (n =6, *p <0.05, **p <0.01, and ***p <0.001). Reprinted from ref189 with permission. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). In summary, the four self-assembled platforms exhibit distinct and complementary roles for RA therapy. Nanoparticles offer design flexibility that enables multi-mechanistic synergy and multi-responsive release; however, their efficacy depends substantially on the EPR effect, and issues of long-term circulation stability and immunogenicity warrant further investigation. Hydrogels are advantageous for sustained intra-articular drug retention and continuous suppression of synovial inflammation, although foreign body response and the long-term biocompatibility of degradation products require more rigorous validation. Micelles facilitate the co-loading of hydrophobic drug pairs with microenvironment-responsive disassembly; nevertheless, their thermodynamic instability below the critical micelle concentration renders them susceptible to premature dissociation upon in vivo dilution. Microneedles physically penetrate the stratum corneum to create transient microchannels, thereby enhancing transdermal drug permeation and enabling non-invasive periarticular deposition; however, their mechanical strength is often inadequate for reliable penetration of the fibrotic skin overlying chronically inflamed joints, and the total deliverable dose per patch remains constrained. Taken together, nanoparticles and micelles tend to be more applicable for systemic targeted delivery, hydrogels for long-acting intra-articular intervention, and microneedles for minimally invasive transdermal precision dosing. These four platforms are mechanistically complementary rather than mutually substitutable, and their rational synergistic integration may provide more comprehensive clinical strategies for addressing the complex pathology of RA. Discussion Rheumatoid arthritis is characterized by abnormal synovial hyperplasia, inflammatory infiltration, and progressive damage to bones and joints. The persistent acidification of the local microenvironment, excessive accumulation of reactive oxygen species, and abnormally high expression of matrix metalloproteinases serve as natural endogenous signals for targeted drug delivery. However, traditional liposomes and polymeric nanocarriers generally suffer from low drug-loading capacities and limitations in single-drug loading, making it difficult to address the complex, multi-mechanism pathological process of rheumatoid arthritis. At the same time, these carriers possess only a single microenvironment-responsive capability, resulting in insufficient precision in lesion recognition; furthermore, the exogenous carrier scaffold is prone to inducing an immune response in the body, posing long-term potential biosafety risks.190 In contrast, self-assembled delivery systems, which rely on hydrogen bonds, hydrophobic interactions, and π-π stacking between drug molecules to self-assemble into nanostructures, offer significant advantages.191 In particular, the carrier-free self-assembly system requires no exogenous excipients, achieves nearly 100% drug-loading efficiency, eliminates carrier-related toxicity, integrates the drug and excipient into a single entity, and significantly enhances biocompatibility and in vivo degradability. The self-assembling delivery system supports the co-assembly of multiple active components, enabling simultaneous synergistic treatment for anti-inflammation, immune regulation, and bone protection. It can also integrate multiple microenvironment-responsive chemical bonds to trigger precise drug release based on lesion-specific signals (such as low pH and high ROS), effectively enhancing local drug accumulation and reducing systemic toxic side effects. Combined with diverse delivery formats such as nanoparticles, hydrogels, and microneedles, the self-assembling delivery system can be adapted for various administration methods, including systemic administration, local intra-articular administration, and minimally invasive transdermal administration. Fully leveraging the pathological characteristics of the lesion site, it enables long-acting, precise treatment and effectively addresses the inherent limitations of traditional delivery technologies. Although self-assembling delivery technologies offer significant advantages, there are still many practical issues that need to be resolved. Specifically, carrier-free systems rely on weak molecular interactions to maintain structural stability and are highly susceptible to structural dissociation caused by body temperature, pH conditions, and ionic interference, resulting in insufficient stability in physiological environments; the space available for drug molecule modification is limited, making it difficult to achieve precise, long-term, controlled drug release; Furthermore, the mechanical strength of the assemblies is poor, making them prone to deformation or rupture under the complex mechanical stresses encountered during in vivo circulation and at the site of the lesion, which makes it difficult to meet the requirements for structural integrity in certain drug delivery scenarios. Carrier-based systems rely on polymers, inorganic materials, or cell membranes to construct their structural scaffolds; however, some of these materials degrade slowly and tend to accumulate in organ and joint tissues, causing chronic irritation;192,193 Acidic fragments produced by the degradation of materials such as PLGA can exacerbate local joint inflammation, and repeated use of exogenous matrices may also trigger immune rejection, reducing the accumulation of the drug at the lesion site,194,195 Complex degradation products can also easily trigger secondary synovial inflammation.196 These structural defects further lead to practical challenges: carrier-free assembly systems are highly sensitive to preparation conditions, making it difficult to ensure batch-to-batch consistency in large-scale production.197 The preparation process for some carrier-based composite systems is complex, and it is difficult to ensure consistent quality standards for hydrogel and microneedle products. At the same time, both types of systems lack dedicated, unified quality evaluation and review standards, and there is currently no systematic data to support their toxicological safety and immunological risks associated with long-term, repeated administration.198 As a result, there are currently no approved nanotherapy drugs specifically for rheumatoid arthritis on the market worldwide. Existing clinical candidate formulations, such as folate receptor-targeted liposomal methotrexate (FBLMTX, NCT06565273) and polyethylene glycol-conjugated liposomal prednisone (Nanocort, NCT00241982), have demonstrated the value of nanodelivery systems for targeted, long-circulating applications. However, safety concerns associated with exogenous carriers have prompted a gradual shift in research focus toward low-toxicity, high-efficacy carrier-free self-assembly technologies. Functional materials such as chitosan, which possess both self-assembly properties and anti-inflammatory activity,199 can simultaneously construct nanostructures and synergistically intervene in inflammatory pathways, thereby achieving the integration of drug and excipient. Compared to the drawbacks of systemic administration—which struggles to maintain effective drug concentrations at the lesion site—local delivery methods such as intra-articular hydrogels and transdermal microneedles offer distinct advantages. Multifunctional thermosensitive hydrogels combined with self-dissolving microneedles based on traditional Chinese medicine can already simultaneously achieve anti-inflammatory effects, bone repair, and low-toxicity delivery; however, current local formulations still rely on synthetic matrices, which cannot eliminate the risk of carrier metabolic accumulation. Against this research backdrop, propylene glycol—which possesses multiple functions including solubilization, permeation enhancement, and sustained-release—has attracted significant attention.161 By regulating the fluidity of the lipid bilayer, it can induce the self-assembly of phospholipids into flexible vesicles, providing a novel approach for developing a local delivery system for rheumatoid arthritis that features high drug loading capacity, mechanical adaptability, and precise responsiveness. Based on this, incorporating the concept of carrier-free self-assembly into microneedle and hydrogel design—relying on the self-assembly of drug or prodrug molecules to form structures while eliminating exogenous structural matrices—has emerged as a highly promising innovative direction. In 2024, research employing a carrier-free strategy demonstrated that soluble microneedles prepared via solution casting using only high-concentration monoclonal antibodies could completely replace traditional polymer matrices, achieving an exceptionally high drug loading capacity of approximately 70% (more than seven times that of traditional microneedles). These microneedles possess sufficient mechanical strength to effectively penetrate the skin, and antibody activity remained stable during a 6-month storage period.200 This provides a solid experimental basis for the research, development, and application of carrier-free protein microneedles. The team led by Li Lin at Anhui Agricultural University has invented a carrier-free self-assembled hydrogel composed of glycyrrhizic acid and polymyxin B (CN202510730349.9), which eliminates the need for an inert carrier, achieves a 100% drug loading rate, and avoids carrier-related adverse reactions. At the same time, the introduction of calcium chloride cross-linking enhances mechanical strength, facilitating adhesion to wound sites and promoting sustained local drug release. This hydrogel demonstrates significantly greater inhibitory activity against MRSA than free drug, and the reduced dosage of polymyxin B alleviates the pressure of drug resistance, providing experimental evidence for the application of carrier-free self-assembling hydrogels. Future research should focus on material optimization, process improvement, and enhanced safety evaluation to continuously drive technological innovation. By employing molecular co-assembly strategies, the structural properties of carrier-free systems can be optimized to improve their stability, mechanical performance, and drug release controllability. For carrier-based systems, the selection of substrate materials and formulation design should be refined by utilizing highly biocompatible and fully degradable materials to mitigate local irritation and cumulative toxicity caused by degradation products. Standardized production parameters should be established through precision manufacturing techniques to address batch variability and uneven formulation consistency, thereby meeting large-scale production requirements. Concurrently, quality standards and regulatory evaluation guidelines tailored for self-assembling delivery systems should be progressively developed, along with comprehensive toxicological and immunotoxicity assessment frameworks for long-term administration. This will strengthen the safety data foundation required for clinical translation, facilitating the steady transition of rheumatoid arthritis-targeted self-assembled delivery technologies from basic research to practical clinical applications. Conclusions and Outlook This review summarizes self-assembled drug delivery systems for rheumatoid arthritis therapy, including self-assembled nanoparticles, micelles, microneedles, and hydrogels. By integrating pathological microenvironment-responsive triggers (eg, low pH, elevated reactive oxygen species, and matrix metalloproteinase overexpression) and co-delivering anti-inflammatory, immunosuppressive, and cartilage-protective agents (eg, curcumin, methotrexate, and dexamethasone), these platforms enable lesion-specific drug release, thereby achieving targeted anti-inflammatory, immunomodulatory, and bone-protective effects while minimizing systemic toxicity. The inherent adaptability of self-assembled systems further facilitates their application across diverse administration routes, ranging from systemic circulation to intra-articular retention and minimally invasive transdermal delivery. Looking forward, the clinical translation of self-assembled delivery technologies relies on the coordinated advancement of material optimization, manufacturing standardization, and the establishment of dedicated safety evaluation frameworks, ultimately accelerating their transition from fundamental research to clinically feasible RA therapeutics. Funding Statement This research was supported by grants from the General Project of Shaanxi Provincial Department of Science and Technology (grant No. 2024SF-YBXM-496), Scientific Research Project of Shaanxi Administration of Traditional Chinese Medicine (grant No. SZY-KJCYC-2025-JC-006), Subject Innovation Team of Shaanxi University of Chinese Medicine (No. 2019-YL11), and Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (grant No. CI2026A05007). Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors report no conflicts of interest in this work. References